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GLOSSARY 
ACIP—Advisory Committee on Immunization Practices. Selected by the Secretary of U.S. Health and 
Human Services, the 15-member ACIP provides advice and guidance to the public health and clinical 
practice communities about controlling vaccine-preventable diseases.  
ACS—The American Community Survey, the nation’s largest annual ongoing demographic survey 
administered by the U.S. Census Bureau, provides communities with the current information they need to 
plan investments and services, including data on educational attainment, income, health insurance, 
commuting, and housing characteristics. 
API—Asian/Native Hawaiian and Other Pacific Islander or Asian/NHPI. API represents the combined 
racial group of Asian or Native Hawaiian and Other Pacific Islander. 
ART—Antiretroviral treatment. The clinical use of antiretroviral agents in the treatment of adults and 
adolescents who are infected with the HIV. 
Asian—Racial group profiled in this report. This group is defined as “A person having origins in any of 
the original peoples of the Far East, Southeast Asia, or the Indian subcontinent including, for example, 
Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and 
Vietnam.” 
CHeCS—Chronic Hepatitis Cohort Study. A long-term cohort study that comprehensively examines the 
clinical characteristics, treatment rates, behavioral qualities, and outcomes of patients for chronic hepatitis 
B and C infections.  
Emerging Infections Program—A CDC-based network that involves state and local health departments 
and academic institutions in population-based surveillance for acute hepatitis A and acute and/or chronic 
hepatitis B and C in the United States 
GISP—Gonococcal Isolate Surveillance Project. Established in 1986 to monitor trends in antimicrobial 
susceptibilities of strains of N. gonorrhoeae in the United States in order to establish a rational basis for 
the selection of gonococcal therapies. GISP is a collaborative project among selected STD clinics, five 
regional laboratories, and CDC. 
HIV and AIDS—Human immunodeficiency virus (HIV) and acquired immune deficiency syndrome 
(AIDS). A person with HIV infection may be diagnosed with AIDS, which usually occurs late in the 
disease course of HIV infection. 
IPP—Infertility Prevention Project. Program that funds chlamydia and gonorrhea screening and treatment 
services for low-income, sexually active women attending family planning, STD, and other women’s 
healthcare clinics. 
M.africanum—Mycobacterium africanum. 
M.bovis—Mycobacterium bovis.  
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M tb—Mycobacterium tuberculosis. A bacterium that causes tuberculosis. 
MDR TB—Multidrug-resistant Tuberculosis.  
MSM—Men who have sex with men. A term used in CDC surveillance systems to indicate males who 
ever had sex with another male, without regard to the nature of the sexual contact (e.g., oral or anal) or to 
how an individual may self-identify in terms of their sexuality. 
MIC—Minimal inhibitory concentration. The lowest antibiotic concentration that prevents bacterial 
growth. 
MMP—Medical Monitoring Project. A CDC surveillance system of HIV-infected persons receiving 
medical care. 
Multiple race—A person self-identifying with more than one race group. 
NETSS—National Electronic Telecommunications System for Surveillance. Computerized public health 
surveillance information system providing CDC with weekly data regarding cases of nationally notifiable 
diseases. 
Native Hawaiian and Other Pacific Islander—Racial group profiled in this report. This group is defined as 
“A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific 
Islands.” 
N. gonorrhoeae—Neisseria gonorrhoeae. A bacterium that causes gonorrhea. 
NHBS—National HIV Behavioral Surveillance System. A CDC surveillance system that collects 
information from groups at high risk for HIV infection.  
NHIS—National Health Interview Survey is a cross-sectional household interview survey administered 
by the CDC’s National Center for Health Statistics to monitor the health of the U.S. population  
NHPI—Native Hawaiian and Other Pacific Islander: racial group profiled in this report. 
NNDSS—National Notifiable Diseases Surveillance System.  
Non-Hispanic American Indian or Alaska Native (Non-Hispanic AIAN)—A person having origins in any 
of the original peoples of North America, and who maintains cultural identification through tribal 
affiliation or community recognition. 
Non-Hispanic Asian—see Asian. 
Non-Hispanic black—A person having origins in any of the black racial groups of Africa. 
Non-Hispanic Native Hawaiian and Other Pacific Islander (Non-Hispanic NHPI)—see Native Hawaiian 
and Other Pacific Islander. 
Non-Hispanic white—A person having origins in any of the original peoples of Europe, North Africa, or 
the Middle East. 
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NTSS—National Tuberculosis Surveillance System. 
OMB—U.S. Office of Management and Budget. A component of the Executive Office of the President of 
the United States, OMB established standards for the collection of race and ethnicity information. 
Primary and secondary (P&S) syphilis—Primary syphilis. A stage of infection with Treponema pallidum 
characterized by one or more chancres (ulcers); chancres might differ considerably in clinical appearance. 
Secondary syphilis: A stage of infection caused by T. pallidum and characterized by localized or diffuse 
mucocutaneous lesions, often with generalized lymphadenopathy. The primary chancre may still be 
present. 
QRNG—Fluoroquinolone-resistant N. gonorrhoeae. Defined as N. gonorrhoeae resistant to ciprofloxacin 
(minimal inhibitory concentration [MIC] >1.0 µg/mL by agar dilution or disk diffusion zone size <27 
mm) or ofloxacin (MIC >2.0 µg/mL or disk diffusion zone size <24 mm) by the National Committee on 
Clinical Laboratory Standards. 
STD—Sexually transmitted diseases are infections that are spread primarily through person-to-person 
sexual contact; some STDs, however, can be transmitted nonsexually, such as transmission from mother-
to-child during pregnancy and childbirth or through blood products. 
SSuN—STD Surveillance Network. In 2005, CDC established SSuN as a dynamic STD surveillance 
network comprised of local enhanced STD surveillance systems that follow common protocols for the 
purpose of improving the capacity of national, state, and local STD programs to detect, monitor, and 
respond rapidly to trends in STDs through enhanced collection, reporting, analysis, visualization, and 
interpretation of disease information. 
TB—Tuberculosis. 
Treponema pallidum—Bacterium that causes syphilis. 
Unprotected insertive anal intercourse—Insertive anal intercourse without a condom or with condom 
breakage. 
USPSTF—U.S. Preventive Services Task Force. An independent panel of non-federal experts in 
prevention and evidence-based medicine. The USPSTF conducts scientific evidence reviews of a broad 
range of clinical preventive healthcare services (such as screening, counseling, and preventive 
medications) and develops recommendations for primary care clinicians and health systems. 
Viral Hepatitis—A term used collectively to refer to a group of viruses that can cause inflammation of the 
liver. In the United States, hepatitis A, B, and C are most commonly reported. 
XDR TB—Extensively Drug-resistant Tuberculosis.  
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BACKGROUND 
This Epidemiologic Profile is the first 
compilation of infectious disease-specific data in 
a single report that focuses on two racial groups 
in the United States: the Asian population and 
the Native Hawaiian and Other Pacific Islander 
population. It has been produced by the National 
Center for HIV/AIDS, Viral Hepatitis, STD, and 
TB Prevention at the Centers for Disease 
Control and Prevention (CDC), and each 
Division represented in the National Center 
participated in the development of the report. 
The U.S. Census Bureau contributed to the 
chapter that describes Asian and Native 
Hawaiian and Other Pacific Islander populations 
who reside in the United States. 
Human immunodeficiency virus (HIV), viral 
hepatitis, sexually transmitted diseases (STDs), 
and tuberculosis (TB) share common risk 
factors, intersect as co-infections, and interact to 
increase transmission and complicate treatment. 
Men who have sex with men are at high risk for 
acquiring STDs and HIV. Persons who inject 
drugs and share their syringes are at risk for 
acquiring HIV and viral hepatitis. And TB takes 
advantage of a person’s impaired ability to fight 
infection or of poor living conditions to spread 
from person to person. A person infected with 
one disease may increase their chance of 
becoming infected with another disease (i.e., co-
infection). For example, STDs that cause skin 
ulceration or mucosal inflammation allow HIV 
infection to occur more easily. Longstanding, 
untreated HIV infection is associated with 
waning immunity and increased risk of TB 
infection. Additionally, co-infection may make 
treating the primary infection more difficult. 
Viral hepatitis complicates HIV co-infection as 
both diseases progress faster, and treatment may 
be more difficult as drug-drug interactions may 
occur or drug resistance may develop. 
Although Asians and Native Hawaiians and 
Other Pacific Islanders currently comprise about 
5% of the U.S. population, the percentage of 
Asians and Native Hawaiians and Other Pacific 
Islanders among persons with these selected 
diseases varies dramatically. For example, for 
hepatitis B and tuberculosis, Asians make up a 
disproportionately large percentage of cases 
(~25%), in excess of their representation in the 
U.S. population. For STDs and HIV, Asians and 
Native Hawaiians and Other Pacific Islanders 
comprise a small percentage of cases (<5%), less 
than their representation in the U.S. population.  
Among Asians and Native Hawaiians and Other 
Pacific Islanders, additional risk factors need to 
be considered. Persons born in a country outside 
the United States (foreign-borna) with endemic 
diseases are more likely to be infected with these 
diseases even if they currently reside in the 
United States. For foreign-born persons, age at 
immigration and fluency of English may 
determine how challenging it will be to contact, 
educate, and treat these individuals and their 
infection. Identifying and addressing stigmatized 
risk behaviors for disease acquisition among 
Asians and Native Hawaiians and Other Pacific 
Islanders, however, may be particularly 
challenging because of social and cultural 
customs within each racial group that suppress 
acknowledgment of these risks and individual 
perception of risk. This unwillingness to 
acknowledge such problems is exacerbated by a 
societal stereotype of Asians and Native 
Hawaiians and Other Pacific Islanders that 
depicts them as being at low risk so that 
healthcare providers do not conduct disease 
testing or ask important questions of patients 
from these groups.  
In 1977, the Office of Management and Budget 
(OMB) set forth a Statistical Policy Directive 
that established standards for the collection of 
race and ethnicity that included: white, black, 
American Indian or Alaskan Native, Asian or 
Pacific Islander, and Hispanic origin.b In 1997, 
after a review of its directive, OMB announced a 
                                                            
a  The definition of “foreign-born” varies somewhat; 
each chapter that uses the term defines it. 
b  http://www.whitehouse.gov/omb/fedreg_race-
ethnicity/. 
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revision to its standard for collection of race and 
ethnicity.c A minimum of five race categories 
were included: American Indian or Alaska 
Native, Asian, black or African American, 
Native Hawaiian or Other Pacific Islander, and 
white. Two categories of ethnicity were also 
used: Hispanic or Latino and not Hispanic or 
Latino (non-Hispanic). Surveillance programs at 
CDC began implementing the new directive in 
partnership with local reporting jurisdictions. At 
the time of this report, most CDC disease-
specific surveillance programs include 
categorization of the Asian population and the 
Native Hawaiian and Other Pacific Islander 
population as separate racial groups. Some 
disease programs continue to report for a 
combined Asian/Native Hawaiian and Other 
Pacific Islander (API) racial group, however. 
When possible, chapter authors have reported 
Asians and Native Hawaiians and Other Pacific 
Islanders separately. In some instances, case 
numbers were too small to allow meaningful 
statistical analysis or data collection processes 
did not allow separation of Asians from Native 
Hawaiians and Other Pacific Islanders; in these 
instances, results are reported in the grouped 
category “API.” For trend analyses that span the 
timeframe in which the directive was 
implemented, Asians and Native Hawaiians and 
Other Pacific Islanders are combined as “API” 
to bridge to data collected under the 1977 OMB 
directive. 
The most currently available national 
surveillance data have been used for this report. 
Interested parties should consult annual 
surveillance reports produced by each Division 
and made available on CDC’s website.d When 
possible, 2010 data have been used, but 
depending on the data source and type of 
analysis, older data have been used to provide a 
                                                            
more comprehensive picture of Asians and 
Native Hawaiians and Other Pacific Islanders 
affected by TB, viral hepatitis, STDs, and HIV. 
This report complements the annual surveillance 
reports produced by each disease-specific 
program by bringing selected information 
together in a single report that profiles non-
Hispanic, single race Asians and Native 
Hawaiians and Other Pacific Islanders. It also 
complements the 2007 Disease Profile,e which 
suggested ways to integrate data and prevention 
resources. By focusing on Asians and Native 
Hawaiians and Other Pacific Islanders, this 2010 
Epidemiologic Profile provides information to 
maximize population-specific prevention and 
disease-specific control efforts. 
                                                            
c  http://www.whitehouse.gov/omb/fedreg_ 
1997standards/. 
d  TB: http://www.cdc.gov/tb/statistics/reports/2010/ 





e  http://www.cdc.gov/nchhstp/Publications/ 
NCHHSTP_Disease_Profile_2007.pdf. 
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CHAPTER 1: ASIANS AND NATIVE HAWAIIANS AND OTHER PACIFIC 
ISLANDERS IN THE UNITED STATES 
INTRODUCTION  
Data from the U.S. decennial census provide a 
rich description of Asians and Native Hawaiians 
and Other Pacific Islanders who reside in the 
United States. These data set a foundation upon 
which readers can compare subsequent disease-
specific prevalence estimates to evaluate 
whether Asians or Native Hawaiians and Other 
Pacific Islanders are overrepresented for a 
particular disease or if other demographic- or 
race-specific factors play a role in disease 
acquisition, disease control, or prevention 
efforts. 
Because Asians and Native Hawaiians and Other 
Pacific Islanders are a diverse, heterogeneous 
group, readers should be cautious about drawing 
inferences about specific subpopulations within 
these groups.  
POPULATION DATA SOURCES 
The U.S. Census Bureau’s annual surveys and 
decennial census provide data that are used to 
enumerate the number of people residing in the 
United States and to describe the demographic, 
social, economic, and housing characteristics of 
the U.S. population and its trends. The decennial 
census, in which each person residing in the 
United States is counted, occurs every 10 years, 
most recently in 2010. Basic demographic 
information, which includes sex, race, and 
ethnicity, is collected in the decennial census.  
Between decennial censuses, the U.S. Census 
releases intercensal estimates each year to 
provide U.S. population estimates by basic 
demographic factors. To provide a description of 
the mid-year 2010 U.S. population by state, age, 
sex, race, and ethnicity, 2009 Vintage Estimates 
have been used in this report.f 
The Census’ American Community Survey 
(ACS) is an annual, nationwide survey that 
includes a sample of all U.S. residents. The ACS 
collects more detailed information such as 
nativity (country of birth), income, education, 
and language spoken at home. The most current 
ACS data at the onset of this research were from 
2009. To determine nativity for foreign-born 
Asians, three years of ACS data have been used, 
2007–2009. 
The U.S. Census collects race and Hispanic 
origin information following the guidance of the 
U.S. Office of Management and Budget’s 
(OMB) 1997 Revisions to the Standards for the 
Classification of Federal Data on Race and 
Ethnicity (1). Starting in 1997, OMB required 
federal agencies to use a minimum of five race 
categories: American Indian or Alaska Native, 
Asian, black or African American, Native 
Hawaiian or Other Pacific Islander, and white. 
Respondents are instructed to select from as 
many of those designations as they feel apply to 
them, but if they are unable to identify with any 
of these five race categories, OMB has approved 
the U.S. Census Bureau’s inclusion of a sixth 
category—Some Other Race—on the Census 
2000 and 2010 Census questionnaires (2). 
In addition to race, ethnicity (i.e., 
Hispanic/Latino origin) is also collected. 
Persons of Hispanic ethnicity may be of any 
single race or combination of races. For the 
Census Bureau’s surveys, identification of race 
and ethnicity is by self-report. 
                                                            
f  Vintage population estimates are produced each 
year by the U.S. Census Bureau on the basis of the 
most recent decennial census. Vintage 2009 
estimates were created in 2009 on the basis of the 
2000 decennial census. At the time this report was 
being prepared, some demographic characteristics 
from the 2010 Census were not available.  
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POPULATION GROUPS IN THIS 
REPORT 
According to the 2010 Census, 308.7 million 
people reside in the United States, reflecting a 
9.7% increase from Census 2000. People who 
listed Asian as their only race and were not of 
Hispanic origin made up 4.7% (14,465,124) of 
the U.S. population. Between 2000 and 2010, 
numbers of non-Hispanic Asians increased 
42.9% (2). People who listed Native Hawaiian 
or Other Pacific Islander as their only race and 
were not of Hispanic origin made up 0.2% 
(481,576) of the U.S. population. From 2000 to 
2010, numbers of non-Hispanic Native 
Hawaiians and Other Pacific Islanders increased 
by 36.2% (2). See Appendix for Table A1.  
For the remainder of this chapter, non-Hispanic 
single race Asians or Native Hawaiians and 
Other Pacific Islanders residing in the United 
States will be profiled. 
Asians 
The term “Asian” is defined by OMB as 
designating people with origins from the Far 
East, Southeast Asia, or the Indian subcontinent, 
including countries such as Cambodia, China, 
India, Japan, Korea, Malaysia, Pakistan, 
Philippines, Thailand, Vietnam, or other Asian 
countries (2). The age distribution of Asians 
who reside in the United States in 2010 is shown 
in Figure 1. Among the almost 15 million non-
Hispanic Asians who resided in the United 
States in 2010, 48% were male. The median age 
for males was 30–34 years, compared with 35–
39 years for females.  
Figure 1. Age distribution of Asians in the United States, 2010*  
 
* Based on intercensal estimates. Population in thousands 
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Table 1. Percentage distribution of Asians, by sex and age group, 2010* 
 Male  Female 
Age group, years %  % 
<5 6.5  5.7 
5–9 6.6  6.0 
10–14 6.4  5.7 
15–19 7.0  6.0 
20–24 8.0  7.1 
25–29 8.4  8.4 
30–34 8.3  8.6 
35–39 8.7  8.9 
40–44 7.8  8.0 
45–49 7.3  7.4 
50–54 6.5  6.9 
55–59 5.5  6.1 
60–64 4.5  5.0 
65–69 3.1  3.4 
70–74 2.3  2.5 
75–79 1.5  1.9 
≥80 1.7  2.5 
* Based on intercensal estimates.  
Figure 2. Distribution of Asians, top 10 states, 2010 
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GEOGRAPHIC DISTRIBUTION OF ASIANS 
According to the 2010 Census, the top ten states 
with the largest populations of Asians are 
California, New York, Texas, New Jersey, 
Illinois, Hawaii, Washington, Florida, Virginia, 
and Massachusetts (see Figure 2). 
The 2010 Census showed that the five 
metropolitan or micropolitan statistical areasg 
with the largest Asian population were the New 
York-Northern New Jersey-Long Island, New 
York-New Jersey-Pennsylvania Metro Area 
(1,860,840); the Los Angeles-Long Beach-Santa 
Ana, California Metro Area (1,858,148); the San 
Francisco-Oakland-Fremont, California Metro 
Area (994,616); the San Jose-Sunnyvale-Santa 
Clara, California Metro Area (566,764); and the 
Chicago-Joliet-Naperville, Illinois-Indiana-
Wisconsin Metro Area (526,857). See the 
Appendix for Table A2, which shows the 20 
metro/micro areas with the largest Asian 
populations in the United States. 
OTHER CHARACTERISTICS OF ASIANS 
According to the 2009 ACS, 9 million or 63% 
(9,152,456/14,465,124) of Asians were foreign-
born,h and accounted for 24% of all foreign-born 
individuals in the United States. Of foreign-born 
Asians, approximately 4.2 million (46%) were 
male and 4.9 million (54%) were female. Using 
2007–2009 ACS data, the top countries of birth 
for foreign-born Asians in the United States 
were, in descending order, China (including 
Hong Kong, Macau, Paracel Islands, and 
Taiwan), Philippines, India, Vietnam, and 
Korea.  
Of 12.7 million Asians ≥5 years of age, 77% 
spoke a language other than English at home, 
and of these, over one-third reported that they 
spoke English “not very well.” 
                                                            
Using 2009 inflation-adjusted dollars, median 
household income was $68,900, and per capita 
income was $30,000 for Asians. Among Asian 
families, 9% had incomes below the poverty 
threshold.i In 2009, 17.2% of Asians did not 
have health insurance (3). Seven percent of 
Asians lived in overcrowded conditions,j 
compared with 3% for the U.S. population. 
Additionally, 89% of Asians had one or more 
vehicles available at their home which was 
comparable to 91% of the U.S. population.  
Educational attainment among Asians is shifted 
toward advanced degrees in comparison with the 
overall U.S. population, with 50% of Asians 
≥25 years of age having at least a bachelor’s 
degree, as do 28% of the general U.S. 
population. More specifically, 30% of the U.S. 
resident Asians had a bachelor’s degree, and 
20% had a graduate or professional degree, 
compared with 18% and 10%, respectively, for 
the general U.S. population. 
Native Hawaiians and Other Pacific 
Islanders 
The OMB definition of “Native Hawaiian or 
Other Pacific Islander” refers to people from 
Guam, Hawaii, Samoa, or Other Pacific Islands 
(2). The age distribution of Native Hawaiians 
and Other Pacific Islanders who resided in the 
United States in 2010 is shown in Figure 3.  
Among the almost 500,000 Native Hawaiians 
and Other Pacific Islanders residing in the 
United States in 2010, 50% were male. The 
median age for males and females was 30–34 
years (see Figure 3 and Table 2).  
                                                            
g  A metropolitan statistical area (Metro Area) 
contains a core urban area of 50,000 or more 
population, and a micropolitan statistical area 
(Micro Area) contains an urban core of at least 
10,000 (but less than 50,000) population 
(http://www.census.gov/population/metro/). 
h  Not a U.S. citizen at birth. 
i  Each year the Office of Management and Budget 
establishes the poverty threshold for the nation. It 
is based on the Consumer Price Index and takes 
into consideration family size and the number of 
children. The 2009 poverty threshold is based on 
family size, the number of children, and whether 
the head of household for 1- or 2-member 
households is elderly. For more information, see 
http://www.census.gov/hhes/www/poverty/data/ 
threshld/thresh09.html.  
j  On the basis of the number of household members 
divided by the number of rooms in the home, >1.0 
persons/room is considered overcrowding. 
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Figure 3.  Age distribution of Native Hawaiians and Other Pacific Islanders in the United 
States, 2010* 
 
* Based on intercensal estimates. Population in thousands 
Table 2.  Distribution of Native Hawaiians and Other Pacific Islanders by sex and age group, 2010* 
 Male  Female 
Age group, years %  % 
<5 7.9  7.8 
5–9 7.9  7.6 
10–14 7.9  7.5 
15–19 8.6  8.4 
20–24 9.8  9.3 
25–29 9.2  8.9 
30–34 8.2  8.0 
35–39 7.3  7.2 
40–44 6.8  6.9 
45–49 6.7  6.9 
50–54 6.0  6.1 
55–59 4.5  4.9 
60–64 3.6  3.8 
65–69 2.3  2.5 
70–74 1.5  1.7 
75–79 0.9  1.2 
≥80 0.8  1.4 
* Based on intercensal estimates. 
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Figure 4. Distribution of Native Hawaiians and Other Pacific Islanders, top 10 states, 2010 
 
GEOGRAPHIC DISTRIBUTION OF NATIVE 
HAWAIIANS AND OTHER PACIFIC 
ISLANDERS 
The top ten states with the largest population of 
Native Hawaiians and Other Pacific Islanders 
were California, Hawaii, Washington, Texas, 
Utah, Nevada, Oregon, Arizona, Florida, and 
New York (see Figure 4). 
The 2010 Census showed that the five 
metropolitan or micropolitan statistical areas 
with the largest Native Hawaiian and Other 
Pacific Islander population were the Honolulu, 
Hawaii Metro Area (86,235); the Los Angeles-
Long Beach-Santa Ana, California Metro 
Area (30,821); the San Francisco-Oakland-
Fremont, California Metro Area (29,761); the 
Seattle-Tacoma-Bellevue, Washington Metro 
Area (27,275); and the Hilo, Hawaii Micro Area 
(20,970). The 20 metro/micro areas with the 
largest Native Hawaiian and Other Pacific 
Islander populations are shown in the Appendix 
in Table A3.  
OTHER CHARACTERISTICS OF NATIVE 
HAWAIIANS AND OTHER PACIFIC 
ISLANDERS 
Over 90,000k or 0.2% of all foreign-
bornh persons in the United States were Native 
Hawaiians and Other Pacific Islanders, 
according to the 2009 ACS. Of this total, males 
slightly outnumbered females, comprising 52% 
(47,600) of the Native Hawaiian and Other 
Pacific Islander population in the United States.  
Of almost 400,000 Native Hawaiians and Other 
Pacific Islanders ≥5 years of age, 43% spoke a 
language other than English at home and of 
these, just over one-tenth reported they spoke 
English “not very well.” 
Using 2009 inflation-adjusted dollars, median 
household income was approximately $53,500, 
and per capita income was $20,000 for Native 
Hawaiians and Other Pacific Islanders, 
compared with $50,000 and $26,000, 
                                                            
k  19% (91,545/481,576) of Native Hawaiians and 
Other Pacific Islanders were foreign-born. 
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respectively, for the general U.S. population. 
Among Native Hawaiian and Other Pacific 
Islander families, 12% had incomes below the 
poverty threshold. In 2009, 17.3% of Native 
Hawaiians and Other Pacific Islanders did not 
have health insurance (3). 
Sixteen percent of Native Hawaiians and Other 
Pacific Islanders lived in overcrowded 
conditions, compared with 3% for the overall 
U.S. population. Additionally, 91% of Native 
Hawaiians and Other Pacific Islanders had one 
or more vehicles available at their home, which 
was comparable with the percentage for the 
overall U.S. population.  
Educational attainment among Native Hawaiians 
and Other Pacific Islanders differed from that for 
the overall U.S. population. Among Native 
Hawaiians and Other Pacific Islanders ≥25 years 
of age, 51% had a high school education or less, 
and 14% had a bachelor’s degree or higher, 
compared with 43% and 28%, respectively, for 
the overall U.S. population. More specifically, 
14% of Native Hawaiians and Other Pacific 
Islanders had not completed high school 
(compared with 15% of the overall U.S. 
population), 37% (compared with 29% of the 
overall U.S. population) had a high school 
diploma or equivalent, 35% (29% U.S.) had 
some college or an associate’s degree, 10% 
(18% U.S.) had a bachelor’s degree, and 4% 
(10% U.S.) had a graduate or professional 
degree.  
DISCUSSION  
The reader should consider several important 
issues that impact the interpretation or 
integration of census versus surveillance data. 
U.S. Census data, notably those for race, are 
generally collected by self-report, whereas 
disease surveillance data are frequently collected 
from secondary data sources such as medical 
records. As such, surveillance data may reflect a 
healthcare provider’s interpretation of a patient’s 
race and ethnicity, which may be different from 
the way in which the patient would self-identify. 
The infectious diseases reported in the 
Epidemiologic Profile 2010 are usually based on 
case data defined by a combination of 
race/ethnicity concepts. For example, the 
surveillance data reflect Asians and Native 
Hawaiians and Other Pacific Islanders who are 
single race and not of Hispanic origin. U.S. 
Census data provide information about Asians 
and Native Hawaiians and Other Pacific 
Islanders who are not of Hispanic origin, as well 
as for those who are of Hispanic origin. 
Currently for Asians who reside in the United 
States, exclusion of those who are of Hispanic 
origin is a reasonable analytic decision, since 
only approximately 1% of Asians are of 
Hispanic origin, but for Native Hawaiians and 
Other Pacific Islanders approximately 11% are 
of Hispanic origin (2). Additionally, the use of 
single-race data for Asians and especially for 
Native Hawaiians and Other Pacific Islanders, 
which are often used by surveillance for disease 
reporting, may be an oversimplification of the 
racial composition of these populations. Among 
non-Hispanic Asians who reside in the United 
States, if Asian in combination with any other 
racial group were included, the population 
would increase by 14%. And the group 
designated as Native Hawaiians and Other 
Pacific Islanders would increase by 53%. For 
consistency, U.S. Census data reported in this 
chapter were restricted to those of a single race 
and of non-Hispanic origin. 
Excluding about one-half of Native Hawaiians 
and Other Pacific Islanders from the description 
of members of those groups who reside in the 
United States may negatively alter the reference 
population the reader is using as a base of 
comparison. Furthermore, this comparison is 
exacerbated by the fact that Census data used for 
Native Hawaiians and Other Pacific Islanders 
originated from those people who reside in the 
United States—not in U.S. territories or other 
dependent areas, many of which are in the 
Pacific Region.  
Asians and Native Hawaiians and Other Pacific 
Islanders are diverse, heterogeneous groups, and 
therefore readers should be cautious when 
drawing inferences about racial subpopulations. 
New data standards recently adopted by the U.S. 
Department of Health and Human Services will 
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help provide more granular information on race 
in the future, but the stability and reliability of 
ever-smaller estimates may overcome the 
intended benefit (4). Additionally, the motivated 
reader could explore racial subgroups by 
selecting subgroups of interest and using data 
from the U.S. Census Bureau’s American 
Community Survey, Asian Population: 2010 
Brief, and Native Hawaiian and Other Pacific 
Islander: 2010 Brief (5,6).  
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CHAPTER 2: TUBERCULOSIS 
OVERVIEW 
Tuberculosis (TB) is an infectious disease 
caused by Mycobacterium tuberculosis, although 
other mycobacteria species (e.g., M. bovis and 
M. africanum) also can cause disease. Most 
commonly, TB is spread when the germs of 
persons with infectious TB disease are released 
into the air (e.g., through coughing, sneezing, 
and talking) and are inhaled by another person. 
The symptoms of TB disease include lethargy, 
weight loss, fever, and night sweats.  
TB disease can occur anywhere in the body; 
however, most disease occurs in the lungs. If the 
disease affects the lungs, other symptoms can 
include coughing, chest pain, and coughing up 
blood. Latent TB infection must be distinguished 
from active TB disease. The term latent TB 
infection is used to describe infection with 
inactive TB germs. Persons that have latent TB 
infection have been exposed to the disease and 
have been infected but have no symptoms. 
These persons are not infectious, although they 
are at risk of the eventual development of active 
disease. In general, persons with active TB (or 
TB disease) are symptomatic and can transmit 
the infection to others. 
According to the 1999–2000 National Health 
and Nutrition Examination Survey, a group of 
health surveys conducted each year among U.S. 
populations, more than 11 million persons have 
latent TB infection (1). An estimated 5%–10% 
of persons with latent infection will eventually 
develop active TB disease. In addition, persons 
infected with human immunodeficiency virus 
(HIV), who also have TB disease, are more 
likely to die without treatment (2). In 2009, 547 
persons died of TB disease, representing a rate 
of 0.2 deaths per 100,000 population (3).  
Most persons with TB disease can be treated 
with a 6- to 12-month course of multidrug 
therapy; however, some cases are caused by 
organisms that are resistant to these medications. 
Multidrug-resistant TB (MDR TB), as defined 
by the World Health Organization, is TB that is 
resistant to at least two of the first-line drugs 
used to treat the disease (i.e., isoniazid and 
rifampin) (4). MDR TB complicates public 
health efforts to control disease. Other cases of 
MDR TB are caused by organisms that are 
resistant not only to first-line antibiotics, but 
also to the best second-line drugs—
fluoroquinolones and at least one of three 
injectable drugs. This subtype of MDR TB, 
known as extensively drug-resistant (XDR) TB, 
occurs very rarely in the United States (5). Less 
than 6 cases of XDR TB have been reported 
annually for the years 2003–2009, whereas 
approximately 100–130 cases of MDR TB were 
reported each year during the same period (3).  
TUBERCULOSIS DATA SOURCES 
The Division of TB Elimination at CDC 
conducts TB surveillance which provides 
national, state, and local level data that helps to 
inform prevention and control efforts. Each year, 
as part of the National Tuberculosis Surveillance 
System (NTSS), all 50 U.S. states and several 
other reporting areas (i.e., the District of 
Columbia, New York City, Puerto Rico, and 
other U.S.-affiliated areas in the Pacific and 
Caribbean) routinely report new cases of TB 
disease to CDC. TB data are then examined by 
race/ethnicity, age, and sex to determine how 
various populations are affected by this disease.  
Data are also examined for other risk factors 
known to be associated with TB (e.g., birth in a 
country with high rates of TB or HIV infection, 
residence in correctional and long-term care 
facilities, homelessness, and drug and alcohol 
abuse). In an effort to more effectively monitor 
TB caused by drug-resistant strains, CDC also 
gathers information regarding drug susceptibility 
testing for culture-confirmed cases.  
Race/ethnicity is a risk factor for TB disease, 
and reporting of race/ethnicity has changed since 
1953 when standardized TB reporting first 
began. In 1985, the NTSS first reported national 
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counts and rates for Asians and Pacific Islanders 
as a combined racial group. In 2003, all federal 
agencies, under the direction of the U.S. Census 
Bureau, began reporting separate population 
estimates for persons of Asian descent and for 
persons of Native Hawaiian and Other Pacific 
Islander descent (NHPI) (6). That year, the 
Division of TB Elimination began reporting 
cases by separate non-Hispanic Asian or non-
Hispanic NHPI race/ethnicity. 
SNAPSHOT 
Population Trends in Race/Ethnicity 
The rate of tuberculosis (new cases per 100,000 
population) among Asians or Native Hawaiians 
and Other Pacific Islanders (API) has always 
been higher than the rate for whites or that 
reported for all TB cases. The total number of 
TB cases reported in the United States in 2000 
was 16,309, a rate of 5.8 new cases for every 
100,000 population (5.8/100,000) (3). In the 
same year, persons of non-Hispanic API race 
had a rate of 31.3 per 100,000 population, more 
than 6 times the overall TB rate and more than 
16 times that reported in non-Hispanic whites 
(1.9/100,000). In the decade since, the case rate 
for TB in the United States has fallen to 3.6 per 
100,000 population, and to 0.9 per 100,000 
members of the non-Hispanic white population 
in 2010.  
Following the implementation of the new 
race/ethnicity reporting standards in 2003, the 
TB case rate for non-Hispanic Asians was 29.9 
per 100,000 population. In 2010, the rate had 
declined 25% to 22.4 per 100,000 population 
(see Figure 5). For non-Hispanic NHPI, the 2003 
TB case rate was 16.2 per 100,000 population, 
but had risen 28% to 20.8 per 100,000 
population in 2010. This represents a higher rate 
than that for all other races combined 
(2.7/100,000) and for non-Hispanic whites 
(0.9/100,000) in 2010 (see Figure 5). In 2010, 
Asians represented 28% of all reported TB cases 
(n=3,143), behind Hispanics (29%, n=3,236), 
and NHPI represented 1% of all reported TB 
cases (n=95).  
Some reporting areas report more TB cases 
among persons of Asian or NHPI descent than 
others. The areas reporting the most TB cases 
among Asians from 2006 to 2010 are California 
(n=5,779, 45% of total cases), New York City 
(n=1,435, 34% of total cases), Texas (n=1,035, 
14% of total cases), and New Jersey (n=777, 
35% of total cases). States with the highest 
percentage of Asians among all their TB cases 
are Hawaii (n=441, 75%), followed by 
California, New Hampshire (n=29, 39%), and 
Virginia (n=531, 36%). States reporting the most 
TB cases among NHPI from 2006 to 2010 are 
Hawaii (n=105, 18% of total cases), California 
(n=67, 0.5% of total cases), and Washington 
(n=55, 4% of total cases). 
U.S. or Foreign Birth 
The Centers for Disease Control first collected 
information on origin of birth (nativity) among 
persons with TB in 1993, and those born outside 
the United States have outnumbered U.S.-born 
persons with TB since 2001. In 1993, 29% of all 
TB cases affected the foreign-born; in 2010, 
60% of all cases were among foreign-born. 
Among Asians (n=26,493) with reported TB 
from 2003 to 2010, 95% were foreign-born. 
Foreign-born, non-Hispanic Asians represent the 
group with the highest proportion of TB cases 
among members of all racial/ethnic groups 
reported in the United States. This proportion 
remained steady throughout the years, with 94% 
of all Asian cases affecting foreign-born persons 
in 2003, and 92% in 2010 (see Figure 6). The 
top four countries of origin among foreign-born 
Asians with TB were the Philippines (26%), 
Vietnam (19%), India (17%), and China (12%).  
Contrasted with Asians, the proportion of TB 
cases among foreign-born NHPI (total cases = 
568) from 2003 to 2010 has been much lower, 
19%. Most NHPI with TB are U.S.-born (80% 
are U.S.-born; country of birth is unknown for 
1%). The NTSS collects incident TB cases from 
the U.S.-affiliated Pacific Islands of Guam, 
Palau, Northern Mariana Islands, American 
Samoa, Marshall Islands, and the Federated 
States of Micronesia. The foreign-born cases 
listed here are reported from the 50 states and 
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the District of Columbia. The proportion of 
foreign-born among NHPI ranged from 9% in 
2009 to 27% in 2006 (see Figure 7). Among all 
reported NHPI TB cases, 60% (n=338) were 
reported as U.S.-born and were from one of the 
six U.S.-affiliated Pacific Islands. The foreign-
born NHPI (n=109) were reported most often 
from Fiji (n=33, 30%), Tonga (n=20, 19%), and 
the Philippines (n=14, 13%).  
Sex and Age 
Overall, there were consistently more males 
reported with TB than females for most 
racial/ethnic groups. From 2003 to 2010, males 
comprised 55% of all Asians and 50% of all 
NHPI reported to have TB. The rate among 
Asian males in 2010 was 26 per 100,000 
population (n=1,786), and 19 per 100,000 
population (n=1,344) for females. Tuberculosis 
rates for males under age 15 were lower than 
those for older Asians (3.8/100,000 for under age 
5, 2.9/100,000 for 5–14 years of age), but the rate 
increased to a high of 76 per 100,000 population 
among males ≥65 years of age (see Figure 8). 
Rates were slightly higher for females than for 
males in the younger age groups (4.2/100,000 for 
ages 5 and under, 3.8/100,000 for 5–14 years of 
age) and rose to a high of 34 per 100,000 
population for Asian females ≥65 years of age. 
From 2003 to 2010, 50% of all NHPI reported to 
have TB were male. In 2010, the highest rate 
among NHPI males occurred in the 15–24-year 
age group (38/100,000), and the next highest 
rate occurred among children <5 years 
(21/100,000) (see Figure 9). Among females, 
similar patterns were seen, with the highest rates 
among children <5 years of age (44/100,000) 
and those 15–24 years of age (37/100,000). 
Other Considerations 
Beyond race/ethnicity, sex, age, and origin of 
birth, other factors can disproportionately affect 
persons with TB. For example, TB occurs more 
often in persons infected with HIV because HIV 
weakens the immune system, greatly increasing 
the likelihood of progression from latent to 
active TB disease. Other risk factors such as 
homelessness, living in a long-term care facility 
or corrections facility, alcoholism and drug 
abuse can increase someone’s likelihood of 
developing active TB disease. Asians and NHPI 
with TB typically have lower rates of infection 
than the national average for persons in all these 
risk categories. One exception to this is MDR 
TB. From 2003 to 2010, Asians with TB had 
nearly twice (1.6%) the percentage of MDR TB 
as all cases of TB (0.9%) and nearly three times 
the rates for non-Hispanic whites (0.6%). The 
rate of MDR TB among NHPI (0.5%) is lower 
than the national percentage. About 6% of 
Asians with TB, the vast majority being foreign-
born, were reported to have a history of TB 
disease, as did <5% of all persons reported to 
have TB disease. In the United States in 2010, 
among persons with no history of TB disease, 
1.2% were diagnosed with MDR TB, whereas 
4.9% of persons with a history of TB disease 
were reported to have MDR TB. This pattern is 
similar among Asians, in that 7% of persons 
with a history of TB were reported with current 
cases of MDR TB (a rate four times higher than 
that for persons with no history of TB).  
DISCUSSION 
The number of tuberculosis cases diagnosed 
among Asians is declining in the United States. 
This may be due to the decline in recent years of 
TB cases among foreign-born persons, 
particularly since 2008 when the number of 
cases among the foreign-born began to decline 
in the United States, along with the overall rate 
of TB cases per 100,000 in the general 
population that had been declining for many 
years. The reasons for this change in trend may 
reflect better overseas pre-immigration 
screening procedures for persons relocating to 
the United States or the fact that fewer foreign-
born persons are relocating to the United States 
in a time of economic recession (7,8). Because 
U.S.-resident Asians with TB are predominately 
foreign-born, this seems a likely explanation for 
their reduction in rate and numbers in the United 
States. However, in 2010, Asians still have the 
second highest rate of TB among all 
racial/ethnic groups, second only to Hispanics. 
Certain minority populations continue to be 
disproportionately affected by TB. Asians are 
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also more likely to have MDR TB than members 
of other racial/ethnic groups. Certain factors are 
associated with this pattern, such as having had 
previous treatment with anti-TB medications and 
being foreign-born. Persons who have been 
treated in the past for TB are more likely to 
develop MDR TB. According to the World 
Health Organization, 15% of previously treated 
patients have MDR TB, which is five times 
higher than the global average of 3% in new 
patients diagnosed with TB (9). Asians with TB 
emigrate from areas of the world where TB is 
prevalent and, therefore, are more likely to have 
a history of TB treatment. 
Recent trends in TB rates among NHPI are 
difficult to assess. Persons of NHPI descent with 
TB are small in number compared with members 
of all other racial/ethnic groups. Fewer than 100 
cases are diagnosed in the United States every 
year. For example, in 2010, 95 cases of TB were 
diagnosed in the United States.  
Tuberculosis incidence is disproportionately 
higher in minority racial/ethnic groups in the 
United States. Ongoing surveillance and 
improved TB control and prevention activities, 
especially among disproportionately affected 
populations, are needed to eliminate TB in the 
United States. 
Note: In all the figures that accompany this 
chapter, all races are non-Hispanic. Starting in 
2003, persons reported race as Asian only or 
Native Hawaiian and Other Pacific Islander 
only. Prior to 2003, these persons were reported 
as one category as a combined Asian or Native 
Hawaiian and Other Pacific Islander, API. 
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Figure 9. Tuberculosis case rates and counts, by age group and sex, Native Hawaiians and Other 
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CHAPTER 3: VIRAL HEPATITIS 
INTRODUCTION 
Viral hepatitis is a term used collectively to refer 
to a group of viruses that can cause 
inflammation of the liver. Although a number of 
hepatitis viruses have been discovered, the most 
common types, which are also currently under 
surveillance in the United States, are hepatitis A, 
B, and C. Infection with any of these viruses can 
result in an acute infection that can cause short-
term illness. However, infection with the 
hepatitis B and C viruses can develop into 
chronic infection that is associated with an 
increased risk of developing cirrhosis or liver 
cancer (1). While the risk of progressing to 
chronic hepatitis B virus infection is inversely 
related to the age at the time of initial infection 
and is diagnosed among about 10% of the adult 
U.S. population (2), 80% of adults who become 
infected with the hepatitis C virus will develop 
chronic infection (3).  
Rates of new infection with acute hepatitis A, B, 
or C virus are at an all-time low primarily as a 
result of successful and effective prevention 
strategies (1). Historically, however, Asians or 
Native Hawaiians and Pacific Islanders (APIs) 
have been disproportionately affected by 
hepatitis B. These populations carry the highest 
burden of chronic infection. The morbidity and 
mortality burden associated with chronic 
hepatitis B and C continues to represent a 
substantial public health problem in the United 
States. During 2001–2006, the incidence of 
hepatocellular carcinoma, a type of liver cancer 
resulting from years of infection with viral 
hepatitis, was highest among APIs when 
compared with blacks, American Indians and 
Alaska Natives, and whites (4). A Markov 
simulation model predicted direct medical costs 
from 2010 to 2019 of about $10.7 billion from 
hepatitis C alone (5).  
Chronic hepatitis B and C infections affect 
millions of Americans. However, due to the 
asymptomatic nature of the disease, many 
people do not realize they are infected until they 
develop liver-related complications many years 
after becoming infected (6). In 2010, the 
Assistant Secretary for Health for the U.S. 
Department of Health and Human Services, Dr. 
Howard Koh, dubbed the number of growing 
cases of chronic hepatitis B and C virus 
infections “the silent epidemic” because of the 
lack of awareness among the general public, at-
risk populations, policymakers, and healthcare 
providers (7).  
VIRAL HEPATITIS DATA SOURCES 
National Surveillance of Acute Viral 
Hepatitis  
The Division of Viral Hepatitis at CDC receives 
reports weekly of cases of acute and chronic 
viral hepatitis from the 50 state health 
departments and the District of Columbia health 
department—and occasionally from the 
territorial health departments—through the 
National Notifiable Diseases Surveillance 
System (NNDSS). The case reports include 
basic information, such as age, race/ethnicity, 
sex, date of onset, date of report, and county of 
residence. Patients of API descent are reported 
under one combined race category. Case reports 
include clinical data, laboratory results, and 
exposure history as optional extended data 
elements. Rates of acute, symptomatic viral 
hepatitis reported through this system are 
included in this report (see Figure 10 and Table 
3) and are calculated using the U.S. Census 
Bureau population estimates. 
Study of Testing Practices and 
Infection Prevalence within U.S. 
Healthcare Organizations  
Investigators from the Chronic Hepatitis Cohort 
Study (CHeCS) collected clinical and 
demographic information from medical and 
billing records of over 1.2 million persons 
enrolled at four integrated healthcare networks 
in the United States (Honolulu, Hawaii; 
Portland, Oregon; Detroit, Michigan; Danville, 
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Pennsylvania). Adults with one or more visits 
during 2006–2008 and 12 months or more of 
continuous follow-up during any period of 
enrollment before 2009 were included in the 
study. A total of 867,589 persons were included 
in the analysis. Of these, 7% (60,255) were 
Asian and 3% (28,531) were Native Hawaiian 
and Other Pacific Islander (NHPI). The 
categories of ever being tested for infection with 
the hepatitis B and C viruses and ever testing 
positive for these viruses were ascertained (8).  
Enhanced Viral Hepatitis Surveillance 
Sites 
CDC currently funds ten sites for viral hepatitis 
surveillance through the Emerging Infections 
Program, a network involving CDC, state and 
local health departments, and academic 
institutions. The ten sites are funded to conduct 
enhanced population-based surveillance for 
acute hepatitis A and acute and/or chronic 
hepatitis B and C in the United States (9). 
During 2005–2007, the Emerging Infections 
Program included six sites that conducted 
surveillance and follow-up of acute hepatitis A, 
B, and C in a population of 29.8 million persons. 
The results from the study describing the 
number and rate of acute, symptomatic hepatitis 
among APIs during 2005–2007 (10) are 
included in this report (see Table 4).  
National Mortality Data 
Death certificates from each state and the 
District of Columbia are compiled by CDC’s 
National Center for Health Statistics to produce 
annual, national mortality data. Demographic 
information—such as age at death, 
race/ethnicity, and sex—and cause of death 
information, including viral hepatitis, are 
included in mortality data (11). The results from 
death certificate studies characterizing place of 
birth among hepatitis B decedents during 2000–
2004 (12) and trends in hepatitis C mortality 
rates during 1995–2004 (13) are included in this 
report. Decedents born outside of the 50 states 
and the District of Columbia were considered 
foreign-born. 
Estimated Births to Hepatitis B Virus-
Infected Mothers 
Birth certificate data from 22 states in 2006 and 
hepatitis B virus infection prevalence estimates 
were used to estimate the number of births to 
women infected with the hepatitis B virus (14). 
U.S.- and Canadian-born women were 
categorized as non-foreign born. Women who 
were born elsewhere were considered foreign-
born and were divided into global regions based 
on country of birth. The medical literature was 
consulted to obtain U.S.-derived prevalence 
estimates of hepatitis B virus infection for non-
foreign-born mothers while regional 
seroprevalence estimates were obtained for 
foreign-born mothers (15–17). These prevalence 
estimates were used to calculate the number of 
estimated births to non-foreign-born and 
foreign-born hepatitis B virus-infected mothers.  
In this chapter, cases of acute viral hepatitis 
among Asians and Native Hawaiians and Other 
Pacific Islanders reported through national 
surveillance are combined under a single race 
category, Asians or Native Hawaiians and Other 
Pacific Islanders (API), and Hispanic ethnicity is 
not examined separately from API race. For the 
CHeCS study, Hispanic ethnicity of Asians and 
Native Hawaiians and Other Pacific Islanders is 
not examined separately from race. All other 
special studies from which data are cited use 
mutually exclusive race/ethnicity categorization 
profiling non-Hispanic, Asians and Native 
Hawaiians and Other Pacific Islanders. 
HEPATITIS A 
About Hepatitis A 
The hepatitis A virus is transmitted from direct 
contact with the stool or blood of an infected 
person or consumption of food or water that has 
been contaminated with fecal matter of an 
infected person. Symptoms such as jaundice, 
dark urine, and nausea are common (10,18). For 
U.S. residents, international travel to a hepatitis 
A-endemic country, household contact with a 
person with hepatitis A, injection drug use, 
being a man who has sex with other men, and 
international adoption of a child infected with 
 Epidemiologic Profile 2010: Asians and Native Hawaiians and Other Pacific Islanders 28 
hepatitis A are all commonly reported risks 
factors for contracting the virus (18). Because 
hepatitis A only exists in an acute form, serious 
complications, such as death from infection, are 
rare. However, certain populations, such as the 
elderly and persons with chronic liver disease, 
are more likely to die if infected (19,20).  
Since 1995, safe and effective vaccines have 
been licensed in the United States to prevent 
hepatitis A. The Advisory Committee on 
Immunization Practices recommends that 
children 12–23 months of age, persons traveling 
to countries where hepatitis A is endemic, men 
who have sex with men, illicit drug users, 
persons with chronic liver disease, and persons 
with occupational risks for infection receive 
hepatitis A vaccination (19). Additionally, post-
exposure prophylaxis, with immunoglobulin, is 
available for persons who were recently exposed 
to hepatitis A and is over 85% effective in 
preventing infection if given within two weeks 
of exposure (21).  
Snapshot 
During 2000–2009, the incidence of acute, 
symptomatic hepatitis A among APIs in the 
United States decreased from 2.1 cases per 
100,000 population in 2000 to 1.0 cases 
per 100,000 population in 2009 (absolute rate 
change, 1.1 cases/100,000), although a slight 
increase was observed from 2007 to 2008 
(see Figure 10). In 2009, acute, symptomatic 
hepatitis A among APIs identified by CDC’s 
National Notifiable Diseases Surveillance 
System accounted for a total of 150 (7.5%) cases 
(see Table 3) (1).  
Of the 1,156 cases of acute, symptomatic 
hepatitis A reported by six U.S. sites conducting 
enhanced hepatitis surveillance from 2005 to 
2007, 79 were among APIs (see Table 4). The 
total incidence rate among APIs was 1.7 cases 
per 100,000 population, almost three times 
higher than blacks and two times higher than 
whites. In New York City, all of the 56 cases of 
hepatitis A occurred among Asians and yielded 
an incidence rate of 2.0 cases per 100,000 
population.  
Sex and Age 
In 2009, males made up 55% of acute, 
symptomatic hepatitis A infections occurring 
among APIs in the United States (see Table 3). 
The incidence rate per 100,000 population was 
highest among males when compared with 
females and among the younger age groups 
when compared with the older age groups. 
Persons 20–29 years of age had the highest 
incidence rate of 2.0 cases per 100,000 
population. 
HEPATITIS B 
About Hepatitis B 
The hepatitis B virus is transmitted through 
exposure of mucous membranes to blood or 
body fluids containing the virus. Modes of 
transmission include sexual contact and sharing 
needles or personal hygiene items such as 
toothbrushes or razors with a person infected 
with the hepatitis B virus (22). Perinatal 
transmission, which plays a critical role in 
sustaining a high prevalence of disease, occurs 
when an infected mother passes on the virus to 
her infant during the birthing process. Chronic 
infection develops for up to 90% of persons 
infected as infants compared with 25%–30% of 
persons who acquire their infection between 1–5 
years of age and about 10% of persons infected 
at >5 years of age (2,23). In many developing 
regions of the world such as Southeast Asia, 
infection acquired in infancy or early childhood 
contributes greatly to the overall burden of 
chronic hepatitis B virus infection in those 
regions.  
From 2007 to 2008, CDC estimated that there 
were approximately 25,000 births each year to 
women in the United States who were 
chronically infected with the hepatitis B virus. 
Of these, an estimated three-fourths were among 
women of API descent (24). However, infection 
at birth often can be prevented if the infant 
receives appropriate post-exposure prophylaxes, 
which are the hepatitis B immune globulin and 
the first dose of the hepatitis B vaccine, 
administered within 12 hours after birth (22).  
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In the United States, trends in the rate of acute 
hepatitis B have declined over time, largely in 
part due to recommendations of the Advisory 
Committee on Immunization Practices 
implemented in 1991 for a comprehensive 
national strategy to prevent the spread of 
hepatitis B virus infection (25,26). The strategy 
recommends routine testing of all pregnant 
women for hepatitis B virus infection, universal 
hepatitis B vaccination of infants beginning at 
birth, catch-up vaccination of previously 
unvaccinated children and adolescents, and 
vaccination and testing of adults who are at an 
increased risk for contracting hepatitis B virus 
infection. Adult populations at risk for acquiring 
hepatitis B include injection drug users, men 
who have sex with other men, healthcare 
workers, dialysis patients, household and sexual 
contacts of persons with hepatitis B, recipients 
of certain blood products, and persons with 
recent multiple sex partners (26). Despite public 
health efforts, hepatitis B vaccination coverage 
is low among U.S. adults who are at risk for 
acquiring infection. Results from the 2009 
National Health Interview Survey indicated that 
only 51% of high-risk adults 18–49 years of age 
had received more than one dose of the hepatitis 
B vaccine. These data also showed that the age 
group 18–20 years had the highest vaccination 
coverage, and that coverage declined with 
increasing age among both high-risk and low-
risk adults (27).  
Snapshot 
During 2000–2009, the incidence of acute, 
symptomatic hepatitis B among APIs in the 
United States fell dramatically from 3.7 
cases/100,000 population in 2000 to 0.7 
cases/100,000 population in 2009 (absolute rate 
change, 3.1 cases/100,000) (see Figure 10). In 
2009, the total number of reported cases among 
APIs identified by CDC’s National Notifiable 
Diseases Surveillance System reached an all-
time low of 98 (2.9%) cases (see Table 3) (1).  
In the CHeCS study from 2006 to 2008, 
approximately 27% of Asians and 26% of 
NHPIs who had no prior documented infection 
with hepatitis B virus when they entered a health 
plan were later tested for infection (see 
Appendix for Tables A4 and A5). Since persons 
included in this study were limited to adults and 
most hepatitis B virus infections among APIs 
occur during birth or early childhood, the vast 
majority of APIs who tested positive for the 
hepatitis B virus were chronically infected. The 
proportion of healthcare-plan members who 
tested positive for hepatitis B virus infection 
ranged from 0.6% among whites to 4.2% among 
Asians (8). Infection prevalence was highest 
among the following groups: Asians (4.2%), 
NHPIs (2.5%), age group 50–59 years (1.9%), 
age group 40–49 years (1.7%), and blacks 
(1.2%). Investigators calculated the expected 
number of hepatitis B virus infections among 
health-plan members who participated in the 
study on the basis of race-adjusted national 
estimates of the prevalence of chronic hepatitis 
B virus infections for 1999–2006 (28). The 
number of hepatitis B virus infections that had 
been diagnosed among health-plan members was 
more than 25% lower than expected, suggesting 
that over a quarter of infected persons might not 
have been identified in the calculations, 
including APIs.  
Sex 
In 2009, males made up 60% of acute, 
symptomatic hepatitis B infections occurring 
among APIs in the United States (see Table 3). 
The incidence per 100,000 population was 1.6 
times higher for males than for females (0.8 vs. 
0.5).  
During 2006–2008, Asians in the CHeCS study 
were comprised of more females than males 
(59% vs. 41%) (see Appendix for Table A4). Of 
the Asian females who had been tested for the 
hepatitis B virus, 4.0% had at least one positive 
test. Of the Asian males who had been tested, 
4.6% had at least one positive test.  
Among NHPIs in the CHeCS study, there were 
more females than males (55% vs. 45%). Of the 
NHPI females who had been tested for the 
hepatitis B virus, 2.2% had at least one positive 
test. Of the NHPI males who had been tested, 
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3.0% had at least one positive test (see Appendix 
for Table A5).  
Age 
In 2009, the incidence rate of acute, 
symptomatic hepatitis B among APIs was lowest 
among persons in the youngest age group, 0–19 
years of age, an age group that is recommended 
for vaccination at birth or during early childhood 
(rate, 0.2 cases/100,000) (see Table 3). The 
highest incidence occurred among young adults 
and persons ≥80 years of age with rates of about 
1 case per 100,000 population. 
During 2006–2008, age groups among Asians in 
the CHeCS study <70 years of age were fairly 
evenly distributed (14.0%–18.8%) (see 
Appendix for Table A4). Asians 40–49 years of 
age and 50–59 years of age who had been tested 
for the hepatitis B virus tested positive for 
infection most frequently (5.0% and 5.8%, 
respectively) compared to other age groups; 
Asians ≥80 years of age tested positive less 
often than any other age group (2.2%). 
The proportion of NHPIs <30 years of age in the 
CHeCS study was 26%, which was greater than 
any other age group (see Appendix for Table 
A5). NHPIs 40–49 years of age and ≥80 years of 
age most often had at least one positive test 
(3.5% and 3.4%, respectively), while NHPIs 70–
79 years of age had the lowest proportion of 
positive tests (0.6%). 
Median Household Income 
Nearly 80% of Asian patients in the CHeCS 
study had a median household income between 
$30,000 and $74,999, according to census tract 
geocode data (see Appendix for Table A4). 
Overall, testing did not vary substantially by 
income bracket. Approximately 3.8%–4.5% of 
Asians in each income bracket who were tested 
for hepatitis B virus infection tested positive.  
Similarly, about 82% of NHPIs in the CHeCS 
study had a median household income between 
$30,000 and $74,999 (see Appendix for Table 
A5). Approximately 1.2%–2.8% of NHPIs in 
each income bracket who had tested for hepatitis 
B virus infection tested positive. 
Mortality 
From 2000 to 2004, the hepatitis B-related 
mortality rate per 100,000 population was about 
three times higher among foreign-born persons 
than among U.S.-born persons (1.0 vs. 0.3 per 
100,000 population, respectively) (see Figure 
11a). In APIs alone, average mortality rates were 
almost four times higher in APIs not born in the 
Unites States than APIs born in the United 
States (2.9 vs. 0.8 per 100,000 population, 
respectively) (see Figure 11b). During 1990–
2004, average hepatitis B-related mortality rates 
per 100,000 population were highest among 
APIs compared to other racial/ethnic groups 
(12). In 2004, rates per 100,000 population were 
8.5 times higher among APIs than among whites 
(2.0 vs. 0.2 per 100,000 population, 
respectively).  
Estimated Births to Infected Mothers  
Foreign-born mothers represented about one-
quarter of all registered births in 22 states in 
2006 (14). Of the foreign-born mothers, 80.6% 
were infected with hepatitis B. Women born in 
regions highly endemic with hepatitis B 
accounted for 69.3% of all estimated hepatitis B 
virus-infected mothers. When stratified by 
region of birth, the highest proportion of 
foreign-born mothers with infection was from 
Southeast Asia (31.2%). Women born in the 
Pacific Islands accounted for 1% of foreign-born 
mothers with infection. Of the mothers born in 
the United States and Canada, regardless of 
hepatitis B virus infection status, API mothers 
accounted for 1.5%. However, of the U.S.- and 
Canadian-born mothers who were infected with 
hepatitis B, APIs accounted for 11.6% (14).  
HEPATITIS C 
About Hepatitis C 
Hepatitis C virus infection, previously identified 
as non-A non-B viral hepatitis until 1995, is the 
most common infection spread through 
contaminated blood in the United States. An 
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estimated 3.2 million persons, representing 1.3% 
of the U.S. population, are chronically infected 
with the hepatitis C virus (29). Chronic hepatitis 
C virus infection is a major cause of liver 
disease (18). In addition, long-term infection 
with the virus is the main factor leading to liver 
transplantation. The major mode of transmission 
in the United States is injection drug use. 
Although there is no vaccine available for 
protection against the virus, the 1998 national 
recommendations for the prevention and control 
of hepatitis C provide guidelines for 
a) preventing transmission; b) identifying, 
counseling, and screening persons at risk; and 
c) providing proper medical evaluation and 
management of infected persons (30). About 
20% of persons who become infected with the 
hepatitis C virus will spontaneously clear the 
virus (3).  
Snapshot 
The incidence of acute, symptomatic hepatitis C 
among APIs in the United States from 2000 to 
2009 is lower than the rates of acute, 
symptomatic hepatitis A and B among APIs for 
the same period. During 2000–2009, API-
specific rates have varied and ranged from a 
high of 0.1 cases per 100,000 population in 2000 
to less than 0.1 cases per 100,000 population in 
2005 and 2007 (see Figure 10). In 2009, there 
were only 5 (0.6%) cases of acute, symptomatic 
hepatitis C among APIs identified by CDC’s 
National Notifiable Diseases Surveillance 
System (see Table 3) (1).  
In the CHeCS testing study during 2006–2008, 
approximately 15% of Asians and 14% of 
NHPIs did not have prior documented infection 
with hepatitis C virus at health plan entry and 
were later tested for infection (see Appendix 
for Tables A6 and A7). Asians were less likely 
than other racial/ethnic groups to test positive 
for hepatitis C virus infection (8).  
Due to the small number of total API cases 
reported to the National Notifiable Diseases 
Surveillance System, API-specific rates for 
acute, symptomatic hepatitis C stratified by sex 
and age group could not be reported.  
Sex 
During 2006–2008, 4.0% of Asian females in 
the CHeCS study who had been tested for 
hepatitis C had at least one positive test (see 
Appendix for Table A6). Asian males tested 
positive as frequently (4.8%) as their female 
counterparts.  
Of the NHPI females who had been tested for 
the hepatitis C virus, 3.5% had at least one 
positive test. Of the NHPI males who had been 
tested, 5.4% had at least one positive test (see 
Appendix for Table A7).  
Age 
During 2006–2008, Asians in the CHeCS study 
50–59 years of age who were tested for hepatitis 
C virus infection tested positive most frequently 
(7.2%) compared to other age groups; Asians 
30–39 years of age tested positive less often than 
any other age group (2.3%) (see Appendix 
for Table A6).  
In the CHeCS study, NHPIs 40–49, 50–59, and 
60–69 years of age tested positive most often 
(5.1%, 7.0%, and 6.5%, respectively) than other 
age groups (see Appendix for Table A7). 
Median Household Income  
Like most participants in the CHeCS study, 
about 78% of Asians had a median household 
income (by census tract data) between $30,000 
and $74,999 (see Appendix for Table A6). The 
proportion testing positive within each income 
bracket was highest among those with a median 
household income of > $30,000, ranging from 
4.7% among those earning $30,000–$49,999 to 
4.0% among those earning > $75,000 annually.  
Approximately 82% of NHPIs in the CHeCS 
study had a median household income between 
$30,000 and $74,999 (see Appendix for Table 
A7). Of about 14%–15% of NHPIs belonging to 
each income bracket who were tested for 
hepatitis C virus infection, approximately 3.7%–
5.7% tested positive.  
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Mortality 
In 2004, APIs had the lowest age-adjusted 
hepatitis C-related mortality rate per 100,000 
population (rate, 1.9; 95% CI, 1.6–2.1) when 
compared with rates for other race/ethnic groups 
(13). From 1995 to 2004, there was a 24.9% 
total percent increase in the age-adjusted 
mortality rate among APIs and an average 
annual rate change of 0.05 deaths per 100,000 
population per year (13).  
DISCUSSION 
APIs residing in the United States are not 
disproportionately affected by acute hepatitis A, 
B, and C or chronic hepatitis C. Based on data 
from the National Notifiable Diseases 
Surveillance System, the 2000–2009 incidence 
rates of acute, symptomatic hepatitis A, B, and C 
among APIs have been on a downward trend. In 
2009, APIs represented 7.5%, 2.9%, and 0.6% of 
acute, symptomatic hepatitis A, B, and C cases, 
respectively. In the CHeCS study, Asian health-
plan members were less likely than other 
race/ethnic groups to have ever been infected 
with the hepatitis C virus. 
Despite low and declining incidence rates, the 
data presented here highlight the substantial 
burden of disease and mortality attributable to 
chronic hepatitis B virus infection among APIs 
in the United States. Asians in the CHeCS study 
had the highest infection prevalence when 
compared with other race/ethnic groups in the 
health plans. Results from population-based 
surveys indicated that there were about 730,000 
adults living with chronic hepatitis B from 1999 
to 2006 in the United States, of whom 43% were 
foreign-born (31). Regions of the world, such as 
Southeast Asia, are considered highly endemic 
for hepatitis B. Infant and early childhood 
infections play a crucial role in sustaining a high 
prevalence in the region (22). Immigration from 
hepatitis B-endemic areas into the United States 
contributes to the growing U.S. burden of 
chronic hepatitis B. Hepatitis B-associated 
mortality is highest among APIs and the foreign-
born. 
Surveillance data from the National Notifiable 
Diseases Surveillance System are subject to 
limitations. First, because APIs are combined 
under a single race category on the case report 
form, assessment of disease occurrence within 
each race group is not possible. Second, only 
data on acute cases are validated and published. 
However, supplementing these data with other 
sources, such as the Emerging Infections 
Program, CHeCS, and the National Vital 
Statistics System, provides valuable information 
regarding the burden of viral hepatitis morbidity 
and mortality among APIs. 
This report highlights the substantial burden of 
chronic hepatitis B virus infection among APIs, 
many of whom are unaware of their infection 
status. Given the data presented here, improved 
viral hepatitis surveillance, culturally 
appropriate public health campaigns, increased 
and wider testing and vaccination of persons at 
high risk, and linkage of infected persons to 
good quality care and treatment are needed in 
order to see measurable declines during this 
epidemic (32).  
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Figure 10. Incidence of acute, symptomatic hepatitis A, B, and C among Asians or Native 
Hawaiians and Other Pacific Islanders (APIs), United States, 2000–2009 
 
Source: National Notifiable Diseases Surveillance System. 
Figures 11a and 11b. Average age-adjusted hepatitis B mortality rates by place of birth, United 
States, 2000–2004 
 
 Foreign-born U.S.-born Foreign-born U.S.-born 
* Asians or Native Hawaiians and Other Pacific Islanders. 
Source: Vogt TM, Wise ME, Shih H, Williams IT. Hepatitis B mortality in the United States, 1990–2004 [Abstract]. 
In: Final Program and Abstracts of the 45th Annual Meeting of the Infectious Diseases Society of America; San 
Diego, CA. October 4–7, 2007; Arlington, VA: Infectious Diseases Society of America; 2007. Abstract 731. 
https://idsa.confex.com/idsa/2007/webprogram/Paper23644.html. Accessed July 19, 2012. 
 Epidemiologic Profile 2010: Asians and Native Hawaiians and Other Pacific Islanders 34 
Table 3. Number of cases and incidence of acute, symptomatic hepatitis A, B, and C, by sex and age 
group among Asians or Native Hawaiians and Other Pacific Islanders, United States, 2009 
 
Hepatitis A Hepatitis B Hepatitis C* 
Demographic characteristics Number Rate† Number Rate† Number Rate† 
Overall 150 1.0 98 0.7 5 <0.1 
Sex§             
   Male 82 1.2 59 0.8 — — 
   Female 67 0.9 38 0.5 — — 
Age group (years)¶             
   0–19 34 0.9 8 0.2 — — 
   20–29 42 2.0 19 0.9 — — 
   30–39 45 1.7 25 1.0 — — 
   40–49 11 0.5 24 1.1 — — 
   50–59 10 0.6 9 0.5 — — 
   60–69 3 0.3 6 0.6 — — 
   70–79 3 0.5 2 0.3 — — 
   80+ 1 0.3 4 1.2 — — 
*  Data could not be produced due to the small number of cases. 
†  Rates are per 100,000 population. 
§ One case of hepatitis A and one case of hepatitis B are not represented in sex category due to missing data. 
¶  One case of hepatitis A and one case of hepatitis B are not represented in age group category due to missing data. 
Source: National Notifiable Diseases Surveillance System 
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Table 4. Number of cases and incidence of acute, symptomatic cases of hepatitis A, by race/ethnicity and reporting site,* United States, 
2005–2007  
 
Colorado Connecticut Minnesota New York State New York City Oregon Row Total 
Variable No. Rate† No. Rate† No. Rate† No. Rate† No. Rate† No. Rate† No. Rate† 
Cases reported 120 0.8 121 1.2 155 1.0 86 0.7 566 2.3 108 1.0 1,156 1.3 
Race/ethnicity                             
  American Indian/Alaska Native 0 0.0 2 8.2 4 2.4 0 0.0 0 0.0 1 0.8 7 1.3 
  Asian/NHPI§ 5 1.4 7 2.0 3 0.6 7 3.2 56 2.0 1 0.2 79 1.7 
  Black 1 0.2 4 0.4 7 1.1 4 0.4 40 0.7 0 0.0 56 0.6 
  White 76 0.7 62 0.8 91 0.7 66 0.6 114 1.3 79 0.9 488 0.8 
  Hispanic 31 1.1 39 3.3 28 4.7 8 1.8 219 3.2 20 1.8 345 2.7 
  Multiple/other 0 0.0 1 0.8 0 0.0 1 0.7 66 22.6 0 0.0 68 5.6 
  Missing 7 — 6 — 22 — 0 — 71 — 7 — 113 — 
* Emerging Infections Program Hepatitis Surveillance Sites, 2005–2007. 
† Rates are per 100,000 population. 
§ Native Hawaiian and Other Pacific Islander. 
Source: Klevens RM, Miller JT, Iqbal K, et al. The evolving epidemiology of hepatitis A in the United States. Arch Intern Med 2010;170(20):1811–1818. 
http://archinte.jamanetwork.com/article.aspx?articleid=226193. Accessed July 19, 2012.
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CHAPTER 4: SEXUALLY TRANSMITTED DISEASES 
INTRODUCTION 
Sexually transmitted diseases (STDs) are among 
the most common infectious diseases in the 
United States and are important causes of 
disease burden. Sexually transmitted diseases 
present enormous health and economic 
consequences. The Centers for Disease Control 
and Prevention (CDC) estimate that 19 million 
new cases of sexually transmitted infections 
occur annually in the United States, with nearly 
half occurring in persons 15–24 years of age (1). 
Direct medical costs associated with STDs in the 
United States are estimated at $15 billion 
annually (2). It is estimated that reported cases 
of STDs represent a fraction of the STD 
infections in the United States, likely reflecting 
limited screening and low disease reporting. 
Many sexually transmitted infections can be 
asymptomatic, causing no recognizable 
symptoms and hence go undiagnosed.  
The spectrum of health consequences from 
STDs ranges from mild acute illness to serious 
long-term complications. Women and infants 
bear a disproportionate burden of STD-
associated complications. Women are less likely 
to have noticeable symptoms and are likely to 
experience long-term consequences—such as 
tubal factor infertility, ectopic pregnancy, and 
chronic pelvic pain—if their STDs are not 
diagnosed and treated. STDs can also result in 
adverse outcomes in pregnancy, including 
spontaneous abortion, still birth, premature birth, 
and congenital infection. Sexually transmitted 
infections enhance the sexual transmission and 
acquisition of HIV infection (3). Improvement in 
the diagnosis, treatment, and management of 
STDs helps prevent disease sequelae and is an 
important component in a comprehensive HIV 
prevention strategy. This chapter will focus on 
three of the most commonly reported STDs: 
chlamydia, gonorrhea and primary and 
secondary (P&S) syphilis.  
SEXUALLY TRANSMITTED DISEASE 
DATA SOURCES 
National Surveillance of Chlamydia, 
Gonorrhea, and Syphilis  
The Division of Sexually Transmitted Disease 
Prevention at CDC has been monitoring the 
prevalence of gonorrhea and syphilis since the 
early 1940s and began monitoring chlamydia in 
the mid-1980s. Currently, chlamydia, gonorrhea, 
and syphilis infections are reported from all 50 
states, the District of Columbia, and U.S. 
dependent areas, including Guam, Puerto Rico, 
and the U.S. Virgin Islands. Nationally 
notifiable STD surveillance data are reported to 
CDC through the National Electronic 
Telecommunications System for Surveillance 
(NETSS). Most of the STD-related morbidity 
data are reported electronically, but a few 
areas—such as Guam and Puerto Rico—
continue to report STD data through summary 
hard-copy forms. Reported cases of STD 
infections reflect the number of infections and 
not the number of people with STDs, since one 
person may account for more than one infection 
during a given reporting period. 
In 2007 the Office of Management and Budget 
(OMB) released final guidance for the collection 
of data on race and ethnicity that allowed for 
a) individuals to self-identify their ethnicity, 
b) individuals to select one or more racial or 
ethnic categories and c) the expansion of 
reporting options to seven categories (American 
Indian or Alaska Native, Asian, black or African 
American, Hispanic, Native Hawaiian or Other 
Pacific Islander, white, and multi-race). 
Following a revision in the NETSS 
implementation guide in April 2008, 
jurisdictions reporting STD data were to collect 
race using these newly expanded racial/ethnic 
groups that included Asian and Native Hawaiian 
and Other Pacific Islander (NHPI). For purposes 
of data reporting, a combined race/ethnicity 
categorization has been used by STD 
 CHAPTER 4: SEXUALLY TRANSMITTED DISEASES 39 
surveillance in which Hispanic/Latino may 
describe any racial group, and each of the five 
standard racial groups can include persons who 
are reported as being of a single race. Although 
many jurisdictions report STD data using this 
format, some jurisdictions have not had the 
capacity to adopt these new standards. Hence, 
for uniformity, race categories for the STD 
morbidity data and the 2000 U.S. Census Bureau 
data are bridged to the five race/ethnicity groups 
specified in the 1977 OMB standards, with 
Asian and NHPI reported as a single combined 
race group of Asian or NHPI (API). The counts 
presented in this report are summations of all 
valid data reported in reporting years 2000–
2010, and hence reflect rates based on reported 
data only. 
STD Surveillance Network (SSuN) 
In 2005, CDC established the STD Surveillance 
Network (SSuN) to improve the capacity of 
national, state, and local STD programs to 
detect, monitor, and respond rapidly to trends in 
STDs through enhanced collection, reporting, 
analysis, visualization, and interpretation of 
disease information. Currently, SSuN is 
composed of 12 collaborating sites in 11 states, 
which together encompass 115 counties and 42 
STD clinics. There are two main activities 
within SSuN, a population-based component and 
a clinic-based component. The population-based 
surveillance activity includes extensive data 
collection on demographics, risk and sexual 
behaviors, and treatment on a random sample of 
patients with reported gonorrhea within the 
site’s jurisdiction. The second activity involves 
the collection of demographic, behavioral, 
clinical, and laboratory information from all 
patients attending 42 STD clinics within the 12 
jurisdictions. 
Gonococcal Isolate Surveillance 
Project (GISP) 
GISP is a CDC-sponsored, sentinel surveillance 
system that monitors antimicrobial 
susceptibilities in Neisseria gonorrhoeae 
through ongoing testing of male urethral 
gonococcal isolates from a systematic sample of 
men at 25–30 STD clinics in the United States. 
The gonococcal isolates are tested against a 
range of antimicrobials to determine 
susceptibility to therapeutically important 
antimicrobial agents, and the results are linked 
to patients’ epidemiologic data.  
Infertility Prevention Project (IPP)  
IPP is a national program funded by CDC in 
collaboration with the Office of Population 
Affairs to prevent chlamydia infections and 
associated reproductive complications in 
women, as well as to monitor test positivity in 
participating clinics. IPP participating sites are 
located across the United States and include 
family planning clinics, STD clinics, community 
health centers, adolescent teen clinics, outreach 
settings, and youth detention facilities. 
Screening criteria and practices vary by clinic, 
but the majority of sites screen all females under 
26 years of age and females ≥26 years of age 
with defined risk factors.  
CHLAMYDIA 
About Chlamydia 
Chlamydia trachomatis infection is the most 
commonly reported condition in the United 
States, with more than 1.3 million infections 
reported in 2010 (4). Age is the strongest 
predictor of infection, with adolescent girls and 
young adult men recording the highest rates. 
Based on estimates from national surveys 
conducted during 1999–2008, chlamydia 
prevalence is 6.8% among sexually active 
females 14–19 years of age (5). Due to the high 
burden of disease and the lack of symptoms in 
most infected persons, CDC recommends annual 
chlamydia screening for all sexually active 
women 25 years of age or younger, and for 
women older than 25 years of age with specific 
risk factors such as a new sex partner or multiple 
sex partners (6). Chlamydia screening is one of 
the most cost-effective yet underused prevention 
services available (7). Although no formal 
national recommendations exist for screening 
young men for chlamydia, their roles in 
transmitting initial and recurrent infections to 
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women are important; a 2006 CDC consultation 
emphasized the importance of screening men in 
certain venues, such as STD clinics and 
corrections facilities (8).  
C. trachomatis causes important diseases in 
men, women, and infants. The primary anatomic 
sites of infection in women are the uterine cervix 
and urethra and for men it is the urethra. Rectal 
infections, acquired through receptive anal 
intercourse, are also common, particularly 
among men who have sex with men (MSM). 
Chlamydia presents the greatest health threat in 
women, primarily through infection that ascends 
from the cervix to involve the uterus and 
fallopian tubes, resulting in pelvic inflammatory 
disease (PID) (9). Both clinically diagnosed 
PID and subclinical upper genital tract 
infection can result in tubal scarring, which 
increases the risk for infertility, ectopic 
pregnancy, and chronic pelvic pain. Chlamydial 
infection can lead to adverse health 
consequences for infants born to infected 
mothers, including conjunctivitis and 
pneumonia. Exposed infants can also develop 
symptomatic infections of the oropharynx, 
genital tract, and rectum. The occurrence of 
neonatal chlamydia represents a failure of 
prevention, since all pregnant women prior to 
delivery should be tested and treated if infected. 
Chlamydia, like other STDs, may increase risk 
for HIV acquisition and transmission (10). 
Snapshot  
Chlamydia case rates among APIs have 
traditionally been lower than the rates for 
members of other race/ethnic groups. In 2010, 
the total number of reported chlamydia cases 
among APIs was 17,188, which accounted for 
approximately 2% of all reported chlamydia 
cases. During 2000–2010, chlamydia case rates 
among APIs increased from 99.5 cases per 
100,000 population to 134.1 cases per 100,000 
(see Figure 12). Although national chlamydia 
case report data suggests a continued increase in 
case reports in APIs and in all other race/ethnic 
groups, it is likely due to improvements in 
reporting, expanded use of increasingly sensitive 
test technology, and better screening of young, 
sexually active women ≤25 years of age.  
SEX AND AGE 
Since 2000, chlamydia case rates among API 
females and males have been gradually 
increasing. Comparing chlamydia rates in 2010 
to 2000, female morbidity has increased 26.3% 
and male morbidity increased 68.5%. Similar to 
other race/ethnicities, API females continue to 
have approximately three times the rate of 
infection of that for API males. Reported 
chlamydia rates for women greatly exceed those 
for men largely because screening programs 
have been primarily directed at women. In 2010, 
the highest rates of chlamydia among APIs are 
among females 15–19 years of age (661.3 per 
100,000) and 20–24 years of age (994.6 per 
100,000), and for males 20–24 years of age 
(275.0 per 100,000) and 25–29 years of age 
(170.6 per 100,000) (see Figure 13).  
TRENDS AMONG WOMEN 15–24 YEARS OF 
AGE WHO ATTEND IPP CLINICS 
Data from prevalence monitoring activities 
indicates modest increases in chlamydia test 
positivity across all race/ethnic groups over the 
past ten years (see Figure 14). Non-Hispanic 
black females have consistently had the highest 
test positivity across all race/ethnic groups. 
Among API women, the median positivity is 
6.5% (range: 6.0–7.9%), higher than among 
white women (median positivity of 4.8%, range: 
3.6–5.5%) and Hispanic women (median 
positivity is 6.1%, range: 5.6–7.5%). Beginning 
in 2007, the majority of IPP sites were collecting 
information consistent with the revisions to the 
OMB directive for the collection of race and 
ethnicity. Examining IPP data from 2007 
through 2010 reveals consistently higher 
chlamydia positivity rates among NHPI women 
than among Asian women. This highlights the 
importance of exploring potential differences in 
risk factors that might explain these differences 
in rates. Approximately 17% of tests per year in 
IPP have missing race/ethnicity so interpretation 
of the data may be difficult. Additionally, trends 
may be influenced by changes in diagnostic test 
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technology (e.g., expanded use of more sensitive 
laboratory tests) and screening coverage.  
GONORRHEA 
About Gonorrhea 
N. gonorrhoeae infection is the second most 
commonly reported condition in the United 
States behind chlamydia. In 2010, there were 
309,341 reports of gonorrhea cases, for an 
incidence of 100.8 per 100,000 population (4). 
From the mid-1970s to the mid-1990s, the rate 
of reported gonorrhea cases in the United States 
declined 74% following implementation of a 
national gonorrhea control program. Between 
1996 and 2006, rates stabilized and between 
2006 and 2010, gonorrhea rates decreased by 
15.8%. Despite these apparent decreases, rates 
of infection remain high among certain 
subgroups, including adolescents, young adults, 
African American men and women, and gay and 
bisexual men. It is important to keep in mind 
that changes in screening practices, reporting 
practices, and use of diagnostic tests with 
different levels of sensitivity and specificity may 
influence the number of case reports of 
infection. 
Men with N. gonorrhoeae infection often 
experience symptoms. Urethritis is the most 
common genitourinary manifestation in men and 
occasionally can be complicated by 
epididymitis. For women, gonococcal infections 
can cause cervicitis and/or urethritis, which may 
or may not be accompanied by clinical signs and 
symptoms. Gonorrhea remains a major cause of 
pelvic inflammatory disease and subsequent 
tubal-factor infertility and ectopic pregnancy 
among women (9,11). Because gonococcal 
infections among women are frequently 
asymptomatic, the U.S. Preventive Services 
Task Force recommends that clinicians screen 
all sexually active women, including those who 
are pregnant, for gonorrhea if they are at an 
increased risk. In addition, for both men and 
women exposed orally or anally, gonococcal 
infection can cause pharyngitis or proctitis, 
which is often asymptomatic. Especially among 
gay men and other MSM, these extragenital sites 
can be a reservoir for transmitting infection. 
Additionally, studies have suggested that 
gonorrhea can facilitate HIV acquisition and 
transmission (3,12).  
Effective treatment of gonorrhea has been 
complicated by the ability of N. gonorrhoeae to 
develop resistance to antimicrobial agents. 
Emergence of gonococcal resistance to penicillin 
and tetracycline occurred during the 1970s and 
became widespread during the early 1980s. In 
the mid to late 1990s, resistance to 
fluoroquinolones was documented first in Asia, 
then emerged in the United States in Hawaii 
followed by other western states. CDC now 
recommends dual therapy for gonorrhea with a 
cephalosporin plus azithromycin or doxycycline. 
Recent increases in minimal inhibitory 
concentrations (MICs) to oral cephalosporins 
have been observed in the United States and are 
concerning as the emergence of resistance to 
cephalosporins would substantially limit 
treatment options for gonorrhea.  
Snapshot 
In 2010, there were 2,314 reported cases of 
gonorrhea among APIs in the United States, 
resulting in a case rate of 18.1 per 100,000 
population (see Figure 15). Comparing the 
single-year rates, gonorrhea case rates among 
APIs in 2010 have decreased by 23.9% since 
2000 (23.8% versus 18.1%). Similar to 
chlamydia case rates, gonorrhea case rates 
among APIs have consistently been lower than 
all other race/ethnic groups. In 2010, the total 
number of reported gonorrhea cases among APIs 
accounted for approximately 1% of all reported 
gonorrhea cases. For comparative purposes, the 
rate for the black population in 2010 (512.2 per 
100,000) was 28 times the rate for the API 
population. 
SEX AND AGE 
Unlike the gender distribution of reported 
chlamydia cases, gonorrhea is more evenly 
distributed among API males and females. For 
2010, the rate for males was 20.1 cases per 
100,000, whereas that for females was 16.1 
cases per 100,000. However, when stratified by 
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age group, API females exceeded males, with 
infection rates for API females 5.5 times higher 
than those for males in the 10–14-year age 
group, and 2.3 times than those for males in the 
20–24-year age group. Similar female to male 
ratios in these age groups are also seen among 
all race/ethnic groups. During 2000–2010, 
gonorrhea case rates decreased by approximately 
25% among API males and females. A 
comparison of age groups indicates that the case 
rate of gonorrhea in 2010 is highest for the 20–
24-year age group, followed by the rate for the 
15–19-year age group. Differences by age 
groups are similar for both males and females.  
GONORRHEA AMONG API MSM IN STD 
SURVEILLANCE NETWORK (SSUN) 
With the exception of reported syphilis cases, 
most nationally notifiable STD surveillance data 
do not include information on sexual behavior. 
However, using SSuN’s population component, 
we are able to access more complete information 
on sex of sex partners (complete for 92% of 
male GC patients interviewed in SSuN, 
compared with 6% of male GC patients reported 
through NETSS in 2010). In weighted analysis 
from the GC patients interviewed, we were able 
to develop national estimates for 2010 that 
indicate that Asians represent 1% of all GC 
cases in SSuN jurisdictions. However, MSM 
account for nearly 70% of the gonorrhea cases 
among API males, suggesting that MSM are at 
the highest risk for gonorrhea in this population.  
Enhanced surveillance collected in STD clinic 
patients in whom sexual orientation data are 
more complete can also be used to supplement 
case report data. Figure 16 presents gonorrhea 
positivity by sex and sex of partner among API 
patients attending SSuN STD clinics in 2010. 
Only those SSuN sites that had >5 API MSM 
attending STD clinics were included. The 
median site-specific gonorrhea prevalence was 
11.7% (range by SSuN site: 7.5%–20.0%) 
among API MSM compared to 2.3% (range: 0–
2.9%) among API men who have sex with 
women only (MSW) and 1.1% (range: 0–2.9%) 
for API women.  
GONORRHEA RESISTANCE IN GONOCOCCAL 
ISOLATE SURVEILLANCE PROJECT (GISP) 
Approximately 64,000 isolates were tested 
during 2000–2010.The percentage of gonorrhea 
isolates with fluoroquinolone-resistant 
N. gonorrhoeae (QRNG) by race/ethnic group in 
the United States during 2000–2010 is shown 
in Figure 17. Shortly after the emergence of 
QRNG in the United States, the prevalence of 
QRNG increased rapidly among gonococcal 
isolates in API and whites as compared to 
blacks. In 2000, 15.7 percent of isolates among 
API were QRNG compared to 0.6% in whites 
and 0.1% in blacks. Although the proportion of 
QRNG among API decreased in 2002 to 4.4%, 
the proportion of QRNG gonococcal isolates 
among API increased to 25.7% in 2010, 
demonstrating a nearly 6-fold increase. Among 
whites, the percentage of isolates with QRNG 
increased steadily to 26.5% in 2010. A similar, 
although less dramatic, increase was seen among 
blacks from 2000 to 2010 (0.1% to 7.4%). 
The increase in QRNG led CDC, in 2007, to 
discontinue recommending any fluoroquinolone 
regimens for the treatment of gonorrhea. Third-
generation cephalosporins are now considered 
one of the classes of antibiotics that are well-
studied and effective against N. gonorrhoeae 
infections in the United States (19). Dual 
therapy with a cephalosporin (ceftriaxone is 
preferred) and either azithromycin or 
doxycycline is recommended by CDC for 
treatment of gonorrhea in adults (20). Recent 
GISP data has documented an increasing trend 
of gonococcal isolates in the United States with 
elevated cefixime MICs (≥0.25 μg/mL) from 
0.2% in 2000 to 1.4% in 2010 and the 
percentage of isolates with elevated ceftriaxone 
MICs (≥0.125 µg/mL) has increased from 0.1% 
to 0.3% during 2000–2010. Although 
proportionally few isolates have exhibited 
elevated MICs for these antimicrobials, 
interesting observations are noted when 
stratified by race/ethnicity (see Figure 18). For 
example, the prevalence of isolates exhibiting 
decreased susceptibility to ceftriaxone (MIC 
≥0.125 μg /mL) is considerably higher among 
API, 1.1% compared to 0.6% of whites and 
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0.2% blacks. Prevalence of isolates with 
elevated cefixime MICs (≥0.25 μg/mL) and 
azithromycin MICs (≥2.0 μg/mL) are higher 
among whites (4.2% and 1.5%) and APIs (3.2% 
and 1.1%, respectively) as compared to blacks 
(0.4% and 0.1%). This epidemiologic pattern of 
increasing percentages of GC isolates with 
elevated cephalosporin and azithromycin MICs 
is particularly concerning since it is similar to 
the pattern seen with GC and fluoroquinolone 
susceptibility shortly before fluoroquinolone-
resistant GC strains emerged over a decade ago. 
SYPHILIS 
About Syphilis 
Syphilis is a sexually transmitted disease caused 
by Treponema pallidum that, if untreated, has a 
long and complicated clinical course. Syphilis 
progresses through defined stages and can last 
for decades but is treatable with penicillin. 
Patients with the earliest symptomatic stages of 
syphilis (primary and secondary, or P&S, 
syphilis) are most likely to present for 
examination and subsequent treatment, with 
symptoms that include genital ulcers or a rash. 
Patients with P&S syphilis can transmit the 
disease sexually. P&S syphilis is followed by a 
long asymptomatic latent stage, followed by a 
late stage that may include serious complications 
such as cardiac or neurological manifestations. 
Latent syphilis cases are generally found 
through screening or partner notification, since 
the patient does not have any symptoms. 
Pregnant women with syphilis can transmit the 
infection to their child, which can cause 
miscarriage, stillbirth, and other serious 
consequences such as deafness, blindness, 
mental retardation, and neonatal death. In 
addition to the significant sequelae of syphilis 
infection, syphilis has been estimated to increase 
HIV transmission 2–9-fold and HIV acquisition 
2–4-fold (13,14).  
Snapshot 
In 2010, the total number of reported P&S 
syphilis cases (201) among APIs accounted for 
less than 2% of all reported P&S syphilis cases. 
Although the total number of P&S syphilis cases 
for APIs was relatively low (compared to other 
races or ethnicities), case rates increased steadily 
during 2000–2009 (0.3/100,000 population to 
1.7/100,000) before decreasing slightly in 2010 
(1.6/100,000). The largest increase in case rates, 
75%, was seen from 2001 to 2002 (0.4/100,000 
compared with 0.7/100,000). Despite these 
apparent increases, the overall rate among APIs 
was the lowest among all races/ethnicities.  
SEX AND AGE 
Surveillance data reveal that the overall increase 
in P&S syphilis rates among API from 2000 to 
2010 largely reflects an increase in rates 
reported among males (see Figure 19). The P&S 
syphilis rates among API males steadily 
increased from a low of 0.6 per 100,000 
population in 2000 to 3.1 per 1000,000 in 2010. 
The P&S syphilis rates among females have 
remained relatively stable since 2000. In 2000, 
the P&S syphilis rate in men was 3.6 times the 
rate in women; by 2010, the P&S syphilis rate in 
men increased to 15 times the rate in women. 
P&S infections are disproportionately found in 
males among other race/ethnic groups as well, 
an indication that syphilis transmission among 
MSM is a factor.  
Unlike chlamydia and gonorrhea, syphilis is not 
predominant in a particular age group. In 2010, 
the P&S syphilis rates among API peaked in the 
20–24-year-old age group for both genders 
(see Figure 20). After the peak, the P&S syphilis 
rates among females continue to decline with 
age, while among males rates peak for a second 
time in the 30–34-year-old age group. The 
higher rates among 20–24-year-old males is a 
trend that first became apparent in 2007.  
SEX AND SEX OF PARTNERS  
Beginning in the early 2000s, increasing cases of 
P&S syphilis were noted primarily among 
MSM. This increase represented a shift from the 
previous epidemiology of P&S syphilis during 
the 1990s, when syphilis primarily occurred 
among heterosexual men and women. In part 
because of this shift, CDC began collecting data 
on the sex of sex partners of reported P&S 
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syphilis cases in 2005. The percentage of cases 
of P&S syphilis among API during 2007–2010 
by sex and sex of sex partner is shown in Figure 
21. These data come from 31 states that reported 
sex of sex partner data for 70% or more of male 
cases of P&S syphilis for each of the years, 
accounting for 89% of male P&S syphilis in the 
United States in 2010. The percentage of cases 
was highest among API MSM, with percentages 
6–7 times higher than among MSW and 12–19 
times higher than among women, depending 
upon year.  
DISCUSSION 
Americans of every age and every geographical, 
racial, cultural, and socioeconomic background 
are affected by STDs. Although each STD has a 
different magnitude of impact on various 
population groups, STD rates among 
Asians/Native Hawaiians and Other Pacific 
Islanders are often among the lowest for each of 
the notifiable STDs. However, the failure to 
recognize the diversity across API ethnic groups 
can contribute to perceptions of a ‘model 
minority’ whose successful acculturation into 
American society implies lack of need for sexual 
health services. APIs are a diverse group and 
classifying them within one race group lessens 
the importance of socioeconomic, cultural, and 
lifestyle variables in explaining variations 
among them. There are limited references to 
national STD data that separate Asians from 
Native Hawaiians and Other Pacific Islanders, 
but when these data are available, differences in 
rates have been noted. For example, IPP data 
demonstrated differences in chlamydia positivity 
rates among Asian women compared to NHPI 
women, which suggests additional studies are 
needed to assess individual and community-level 
risk factors that might help to explain some of 
these differences.  
In addition to recognizing the diversity within 
the API community, it is also important to note 
that certain subpopulations within the API 
community, such as MSM and youth, are 
particularly affected by STDs. Based on case 
report and enhanced surveillance data, API 
MSM are disproportionately affected by 
gonorrhea and syphilis infections when 
compared with API MSW and women. 
Investigations of STDs and HIV among API 
MSM have found that they are more likely to 
engage in unprotected sex when they have not 
been in the United States for very long or do not 
identify as being gay/homosexual (15,16). 
Youth, particularly women, also suffer 
disproportionately from STDs regardless of 
race/ethnicity. Existing literature may provide 
some insight into the behavioral and contextual 
factors that may influence API adolescents and 
young adults’ STD risk. Several researchers 
have concluded that API share certain cultural 
characteristics—such as sexual activity only 
within the context of marriage, the importance 
of family with an emphasis on propriety and 
social codes, and an absence of open discussions 
of sexuality—that may have significant impact 
on sexual health of APIs, particularly among 
youth (17–21). API youth appear to have a 
somewhat lower risk of STD acquisition than do 
other racial groups because a lower proportion 
engage in sexual activity (22,23). However, 
APIs who are sexually experienced do not differ 
in age at sexual debut or lifetime sexual partners 
as compared to white adolescents. Additionally, 
sexually experienced APIs are more likely than 
their white counterparts to have had multiple sex 
partners in the recent past (24). Data from the 
National Longitudinal Study of Adolescent 
Health found an overall 9% prevalence of any 
STD among API study participants, with a 
higher occurrence of STDs among young 
women compared with young men (13% vs. 4%) 
(25). And while national chlamydia and 
gonorrhea rates are higher in young women than 
young men among all racial/ethnic groups, API 
women may have broader and more racially 
diverse sexual networks than men, exposing 
them to more STDs (19). 
The presence of antibiotic-resistant Neisseria 
gonorrhoeae is a public health concern in the 
management of the infection. Over the years, 
this organism has acquired resistance to a 
number of antibiotics, including penicillin and 
fluoroquinolones, and historically much of this 
resistance has first appeared in the Western 
Pacific and Southeast Asia regions. During the 
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1970s and 1980s, the emergence and widespread 
dissemination of strains of N. gonorrhoeae 
resistant to penicillin necessitated abandoning 
these antimicrobials as treatment for gonorrhea 
in the United States. In the mid-1990s, QRNG 
was first documented in Hawaii, likely due to 
importation from tourists and immigrants from 
the Western Pacific and Southeast Asia (26,27). 
Since 2001, several reports of possible 
cephalosporin treatment failures have been 
identified in Japan (28–30). Additionally, trends 
in decreasing gonococcal susceptibility to 
cephalosporins over time have also been 
described, primarily in Asia (31–33). Given the 
historical experience with N. gonorrhoeae, it is 
likely that resistance to cephalosporins will 
eventually develop first among Asians and 
Asian Americans. The ability to monitor 
emerging strains of antibiotic-resistant 
N. gonorrhoeae arising from Asia and Pacific 
regions may provide early warning signs for the 
continental United States.  
Although APIs as a group appear to be at less 
sexual risk, substantial numbers of APIs engage 
in sexual activities that place them at risk for 
acquisition and transmission of STDs. 
Additionally, the possibility that APIs may 
develop risk profiles comparable to other groups 
once they initiate sexual activity reinforces the 
importance of providing them with the culturally 
sensitive information and skills they need to 
make informed decisions. Education, prevention, 
and treatment of STDs are important for the API 
population not only to prevent sequelae from 
STD infection, but also because of the 
relationship of STDs with HIV infection and 
transmission.  
Figure 12. Chlamydia case rates and counts among Asians or Native Hawaiians and Other Pacific 
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Figure 13. Chlamydia case rates among Asians or Native Hawaiians and Other Pacific Islanders 

























Figure 14. Chlamydia positivity among 15–24-year-old women in Infertility Prevention Project 
clinics, by race, 2000–2010 
 
*  API=Asian/Native Hawaiian and Other Pacific Islander; positivity rates for APIs are available from 2000 to 2006. 
†  AIAN=American Indian/Alaska Native. 
§  UNK=Unknown race.  
¶  NHPI=Native Hawaiian/Other Pacific Islander; positivity rates for NHPIs and Asians are available from 2007 to 
2010. 
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Figure 15. Gonorrhea case rates and counts among Asians or Native Hawaiians and Other Pacific 






































Total No. of Cases Case Rate
Figure 16. Gonorrhea test positivity among Asian or Native Hawaiian and Other Pacific Islander 
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Note: Only sites with >5 MSM were included.  
MSM=men who have sex with men; MSW=men who have sex with women only. 
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Figure 17. Prevalence of QRNG among Neisseria gonorrhoeae isolates by year and race, GISP, 
2000–2010 
 
* Native Hawaiian and Other Pacific Islander. 
QRNG=Fluoroquinolone-resistant Neisseria gonorrhoeae; GISP=Gonococcal Isolate Surveillance Project. 
Figure 18. Percentage of gonorrhea isolates with cefixime MICs ≥0.25 µg/mL, ceftriaxone 
MICs ≥0.125 µg/mL, and azithromycin MICs ≥2 µg/mL by race/ethnicity—Gonococcal 





















MIC=Minimal inhibitory concentration. 
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Figure 19. Primary and secondary syphilis case rates by sex, Asians or Native Hawaiians and 























Figure 20. Primary and secondary syphilis case rates by sex and age group, Asians or Native 
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Figure 21. Percentage of primary and secondary syphilis cases among Asian or Native Hawaiian 

























* States reporting sex of sex partner for 70% or more of reported P&S syphilis cases among API males. 
MSM=men who have sex with men; MSW=men who have sex with women only. 
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CHAPTER 5: HIV and AIDS
OVERVIEW 
Human immunodeficiency virus (HIV) can 
infect persons of any age and race. The virus is 
most commonly transmitted through sex with an 
infected partner; injection drugs using a 
contaminated syringe; perinatal exposure from 
an HIV-infected mother to child at birth or 
through breast feeding; or transfusion or 
organ/tissue transplantation from an infected 
donor. Initially, acute HIV infection may present 
as an influenza-like illness or other viral illness 
with a range of symptoms that usually last for a 
few days to several weeks and then resolve. 
Over time, however, there is progressive 
destruction of the immune system—specifically, 
CD4+ T-lymphocytes, a type of white blood cell 
that fights infection, are destroyed. When the 
number of CD4+ T-lymphocytes declines to 
very low levels, certain opportunistic infections, 
cancers, or other conditions that are associated 
with acquired immunodeficiency syndrome 
(AIDS) may develop. The spectrum of HIV 
infection—from acute infection to death, with or 
without the development of AIDS—is called 
HIV disease. 
In the absence of a cure, efforts to prevent 
primary infection remain critical in controlling 
the HIV epidemic. Prevention measures are 
developed for specific at-risk populations, with 
the basic strategies of identifying HIV infection 
soon after infection, linking infected persons to 
care early during the course of infection and 
retaining them in care, and providing prevention 
services for both HIV-infected and HIV-
uninfected persons. Because HIV infection is 
predominantly transmitted through sexual 
intercourse or injection drug use, a great deal of 
effort is focused on reducing these modes of 
HIV transmission with behavioral 
interventions (1). Recently, there also has been 
an increasing recognition of the role 
of antiretroviral treatment (ART) in HIV 
prevention; in addition to improving or 
maintaining the clinical status of and the quality 
of life for HIV-infected persons, ART can 
suppress HIV viral loads to levels that are 
associated with a substantial decreased risk for 
HIV transmission (2–4). 
As prevention interventions are implemented or 
modified for maximal impact, it is important to 
monitor their effectiveness in terms of the trend 
in HIV infection rates, prevalence of HIV risk 
behaviors or health-seeking behaviors, and the 
clinical status of and quality of care received by 
HIV-infected persons. At the Centers for 
Disease Control and Prevention (CDC), 
surveillance systems that are central to 
monitoring key aspects of the continually 
evolving HIV epidemic include the National 
HIV Surveillance System, the Medical 
Monitoring Project (MMP), and the National 
HIV Behavioral Surveillance System (NHBS). 
HIV and AIDS DATA SOURCES 
Burden of HIV Disease 
The Division of HIV/AIDS Prevention at CDC 
is responsible for monitoring the U.S. epidemic. 
AIDS diagnoses and deaths among persons with 
AIDS have been reported to CDC by all 50 
states, the District of Columbia, and U.S. 
dependent areas since the 1980s. HIV reporting 
includes the diagnosis of HIV infection, 
irrespective of the stage of HIV disease. 
Confidential, name-based HIV reporting began 
in a limited number of states in the mid-1980s 
and has been implemented by the remaining 
reporting jurisdictions over time. By April 2008, 
all states, the District of Columbia, and six 
dependent areas had implemented such 
reporting. At the time of this report, 46 states 
and 5 dependent areas had mature (i.e., 
confidential, name-based reporting in place for 
at least 4 years) and stable HIV data through 
2010 that could be used for the present 
analysis (5). These areas include: Alabama, 
Alaska, Arizona, Arkansas, California, 
Colorado, Connecticut, Delaware, Florida, 
Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, 
Kentucky, Louisiana, Maine, Michigan, 
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Minnesota, Mississippi, Missouri, Montana, 
Nebraska, New Hampshire, New Jersey, New 
Mexico, New York, Nevada, North Carolina, 
North Dakota, Ohio, Oklahoma, Oregon, 
Pennsylvania, Rhode Island, South Carolina, 
South Dakota, Tennessee, Texas, Utah, Virginia, 
Washington, West Virginia, Wisconsin, and 
Wyoming and 5 U.S. dependent areas 
(American Samoa, Guam, the Northern Mariana 
Islands, Puerto Rico, and the U.S. Virgin 
Islandsl). 
Beginning in January 2003, following the Office 
of Management and Budget (OMB) directive, 
the collection of data on race uses at least five 
racial groups, which include Asian and Native 
Hawaiian or Other Pacific Islander (NHPI). Two 
categories of ethnicity, Hispanic or non-
Hispanic, are also used. For purposes of data 
reporting, a combined race/ethnicity 
categorization has been used by HIV 
surveillance in which Hispanics/Latinos may be 
of any racial group and each of the five standard 
OMB racial groups includes non-Hispanic 
persons who were reported with a single race. 
When Asians and NHPIs cannot be reported 
separately, a combined Asian/Native Hawaiian 
and Other Pacific Islander (API) group is used.  
Surveillance data may not be complete—risk 
exposures for transmission categories may be 
missing or unknown (i.e., no risk factor reported 
or identified). In such cases, multiple imputation 
is used to assign risk exposure information to 
persons with HIV disease who are reported 
without this information (5).  
The time from initial diagnosis of HIV until the 
case is reported to CDC is the reporting lag time 
and may be as long as 2 to 3 years (5). Statistical 
adjustments are made to the case counts to 
account for this delay and are reported as 
estimated numbers. Because of the delay for 
death ascertainment, an 18-month lag time is 
allowed so deaths described in this analysis are 
accounted for through June 2009. Thus, 
                                                            
estimates for persons living with HIV or AIDS 
that used 2010 data are limited to the period 
ending December 31, 2009. Estimates based on 
data other than 2010 data are referenced. 
Although adjustments are made to surveillance 
data for incomplete risk information and for 
delayed reporting, as noted above, the data do 
not include an adjustment to account for persons 
who are HIV infected and not reported, either 
because they are undiagnosed or tested 
anonymously. 
Rates have been calculated using U.S. Census 
Bureau population estimates. 
MMP: HIV-Infected Persons in Care  
MMP is a multi-site supplemental surveillance 
project developed to provide nationally and 
locally representative estimates of behaviors, 
clinical characteristics, and quality of care of 
HIV-infected persons who are receiving care. 
The project began with a pilot phase in 2005 and 
was fully implemented in 2007 (6,7). 
MMP data are collected through interviews and 
medical record abstractions on an annual 
probability sample of persons in care for HIV 
infection in the United States. Details on the 
design and methods of MMP have been 
previously reported (7,8). Briefly, eligible 
persons are HIV-infected individuals ≥18 years 
of age who receive outpatient care at an HIV 
care facility from January through April during 
the year of an MMP cycle. Data collected 
through interviews focus on behavioral issues, 
including behaviors that may facilitate HIV 
transmission; health seeking behaviors; 
utilization of HIV-related medical and 
prevention services; and adherence to 
medication regimens. Data collected through 
medical record abstractions focus on clinical 
conditions that result from a person’s HIV 
infection or medications taken, laboratory tests 
performed and their results, and the type and 
quality of HIV care and support services these 
individuals receive.  
The MMP data presented in this report are from 
interviews conducted during the 2007 and 2008 
l  When AIDS cases were reported and data were 
available, data from the Republic of Palau have 
been included for a total of 6 U.S. dependent areas. 
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MMP cycles (data collected from June 2007 to 
April 2009) in 26 project areas: California; 
Chicago, Illinois; Delaware; Florida; Georgia; 
Houston, Texas; Illinois; Indiana, Los Angeles 
County, California; Maryland; Massachusetts; 
Michigan; Mississippi; New Jersey; New York; 
New York City, New York; North Carolina; 
Oregon; Pennsylvania; Philadelphia, 
Pennsylvania; Puerto Rico; San Francisco, 
California; South Carolina; Texas; Virginia; and 
Washington.  
MMP collects information on race/ethnicity in 
accordance with the 2003 OMB directive. MMP 
also reports data on race/ethnicity using a 
combined categorization similar to that 
described above for the National HIV 
Surveillance System. For the MMP data in this 
report, however, the Asian and NHPI categories 
are combined because of the small number of 
MMP participants in each of these categories. In 
addition, several participants who reported being 
both Asian and NHPI are included in the 
descriptive analysis of API persons in care for 
HIV infection. 
NHBS: At-Risk Populations 
NHBS is a behavioral surveillance system 
developed in recognition of the need for 
information on populations at high risk for 
acquiring HIV infection. The data presented in 
this report were collected in the 2008 NHBS 
cycle, which focused on men who have sex with 
men (MSM).  
In 2008, NHBS project activities were 
conducted in 21 urban areas. These areas were 
selected based on high burden of AIDS and 
included approximately 60% of all prevalent 
urban U.S. AIDS cases in 2008 (9). Men were 
sampled using venue-based (e.g., bars, clubs, 
organizations, and street locations), time-space 
sampling methods (10). Those eligible for 
participation were ≥18 years of age, residents of 
the selected geographic area, and able to 
complete an in-person interview in English or 
Spanish. For this report, analyses were limited to 
men who reported having sex with another man 
in the 12 months preceding the interview. The 
interview consisted of questions about sex, drug 
use, HIV testing behaviors, and use of HIV 
prevention services. Respondents, regardless of 
self-reported HIV infection status, were also 
offered anonymous HIV testing, given the 
opportunity to receive their test results, and 
anonymously referred to care when appropriate.  
Like MMP, NHBS collects information on 
race/ethnicity in accordance with the 2003 OMB 
directive. In addition, specific information on 
the ancestry of Hispanic participants is collected. 
For the NHBS data in this report, the Asian and 
NHPI categories were combined due to the small 
number of NHPI participants, which limits the 
ability to further categorize this group by 
different characteristics in a descriptive analysis. 
SNAPSHOT 
Persons with HIV Disease 
In 2010, 818 (1.7%m) Asians and 67 (0.1%) 
NHPIs were diagnosed with HIV infection in 46 
states and 5 dependent areas. The rate of HIV 
diagnoses for Asians has remained stable over 
time from 6.5 per 100,000 population in 2007 to 
6.5 per 100,000 population in 2010 (see Figure 
22). Among NHPIs, the rate of HIV diagnoses 
changed little from 21.3 per 1000,000 
population in 2007 to 19.3 per 100,000 
population in 2010 (see Figure 23). The 
estimated number of AIDS diagnoses in the 
United States, the District of Columbia, and 
6 dependent areas for Asians and NHPIs in 2010 
were 480 and 45, respectively, and contributed 
to an estimated cumulative total of 8,795 and 
889, respectively, diagnosed with AIDS from 
the start of the epidemic. 
At the end of 2009, there were 8,422 Asians and 
620 NHPIs estimated to be living with HIV 
disease in the United States and 5 dependent 
areas. An estimated 5,112 Asians and 481 
NHPIs were living with AIDS in the United 
States and 6 dependent areas at the end of 2009. 
The geographic distribution of persons ≥13 
years of age who were living with AIDS at the 
                                                            
m  Of all HIV diagnoses in 2010. 
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end of 2009 varied by race. Among Asians, the 
top 10 states with the greatest number of persons 
living with AIDS were (in decreasing order) 
California, New York, Texas, Hawaii, Illinois, 
Washington, Massachusetts, Virginia, Florida, 
and New Jersey. Among NHPIs living with 
AIDS, states (in decreasing order) were 
California, Hawaii, Washington, Texas, Florida, 
then equally Nevada and Maryland, followed by 
equal numbers in New York and Pennsylvania. 
SEX AND AGE 
The percentage of men and women ≥13 years of 
age living with HIV disease at the end of 2009 
was similar for Asians and NHPIs: 
approximately 80% were men and 20% were 
women. Over 60% of HIV-infected Asians and 
NHPIs were 30–49 years of age. One percent or 
less of Asians and NHPIs living with HIV 
were <20 years of age at the end of 2009 
(see Table 5). 
Previously published data that examined the 
estimated annual percentage change for HIV 
diagnoses from 2001 to 2008 reported a 
significant average annual increase of 5.1% for 
API men (11). Among API women, there was no 
substantial change in the rate of HIV diagnoses 
during this period.  
FOREIGN-BORN 
Foreign-born status is based on country of birth 
and is defined as any birth that occurs outside 
the United States and its territories. A recent 
analysis of National HIV Surveillance System 
data from 46 states and 5 territories in which 
country of birth information was available 
estimated that 1,987 (64%) Asians who were 
diagnosed with HIV infection and reported to 
CDC from 2007 to 2010 were foreign-born (12). 
In contrast, 89 (32%) NHPIs diagnosed with 
HIV infection during the same period were 
reported as foreign-born (12). 
Among APIs diagnosed with AIDS from 1999 
to 2002, the most common countries of birth 
outside the United States were India, Vietnam, 
the Philippines, Thailand, and Cambodia (13). 
TRANSMISSION CATEGORY 
Transmission categories are routes of HIV 
transmission that are believed to have led to HIV 
infection. Individuals may have more than one 
risk factor for HIV infection, but—for 
surveillance purposes—risks are categorized in a 
hierarchy so that each individual is classified 
into a single transmission category. The most 
commonly reported categories of HIV 
transmission in 2010 for Asians and NHPIs vary 
by age and gender. Among Asian men ≥13 years 
of age, sex with another man accounted for 
approximately 80% of cases and heterosexual 
contact for about 9%. Among NHPI men, sex 
with another man accounted for almost 85% of 
cases and heterosexual contact for 
approximately 6% of cases. For Asian and NHPI 
women, heterosexual contact was the most 
prevalent risk factor. Among Asian women, 
heterosexual contact accounted for over 85% 
and injection drug use for about 9% of cases. 
Among NHPI women, injection drug use 
accounted for over 15% and heterosexual 
contact approximately 80% of cases (see Table 
6). Among Asian and NHPI children, <13 years 
of age, perinatal exposure was the most 
prevalent risk exposure. 
STAGE AT TIME OF HIV DIAGNOSIS 
Immune function, as assessed by CD4+ T-
lymphocyte count at the time of HIV diagnosis, 
may be used to stage HIV infection and make 
general inferences of the length of time since 
HIV acquisition. Beyond the period of acute 
HIV infection, normal or nearly normal CD4+ 
T-lymphocyte counts in ART-naïve persons 
suggests the diagnosis of HIV infection was 
made early in the course of HIV disease; a low 
CD4+ T-lymphocyte count that meets the 
serological criteria for AIDS (<200 cells/µL) 
suggests longstanding HIV infection. CD4+ T-
lymphocyte counts of persons diagnosed 
with HIV infection in 2007 and subsequently 
assessed for immune function within 12 months 
of diagnosis varied by race/ethnicity. The 
median CD4+ T-lymphocyte count for Asians 
was 182 cells/µL (interquartile range [IQR]: 67–
358 cells/µL) and for NHPIs was 268 cells/µL 
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(IQR: 114–396), in contrast to 248 cells/µL 
(IQR: 99–434) for whites (14).  
MORTALITY  
Cumulative deaths among Asians and NHPIs 
diagnosed and reported as having AIDS, from 
the start of the epidemic through 2009, have 
been estimated to be 3,203 and 363, 
respectively. 
PERSONS IN CARE FOR HIV DISEASE 
Among 6,916 participants in the 2007 and 2008 
MMP cycles, 94 (1%) were APIs. Of these, 55 
(58.5%) were Asian, 77 (81.9%) were male, 65 
(69.1%) were 35–54 years of age, 66 (70.2%) 
had completed some education beyond high 
school, and 48 (51.1%) had been diagnosed with 
HIV infection for ≥10 years (see Appendix 
for Table A8). A total of 38 (40.4%) participants 
were born outside of the United States; the 
country of birth varied greatly, with the most 
common being the Philippines (n=10) and 
Vietnam (n=5). In the 12 months prior to 
participating in MMP, nearly half (47.9%) of 
API participants reported receiving public 
assistance despite the fact that 85.1% of all API 
participants reported having health insurance or 
coverage.  
Sixty-seven percent of API participants reported 
having their first visit for HIV medical care 
within 3 months following diagnosis. Among 
API participants, 87.2% reported being on ART 
during the 12 months before interview, 40.4% 
reported that their most recent CD4+ T-
lymphocyte count was ≥500 cells/µL; 75.5% 
reported that their lowest CD4+ T-lymphocyte 
count was <500 cells/µL (see Figure 24); and 
63.8% reported that their most recent HIV viral 
load was undetectable. 
The ancillary services needs most commonly 
reported among API participants in the 
preceding 12 months were HIV case 
management services (40.4%), mental health 
counseling (30.9%), dental care (27.7%), social 
services (26.6%), and transportation assistance 
(26.6%). Among API participants who reported 
needs for the aforementioned ancillary services, 
<15% of those who needed HIV case 
management, 28.0% of those who needed 
mental health counseling, 24.1% of those who 
needed social services, 34.6% of those who 
needed dental care, and 20.0% who needed 
transportation assistance reported that they had 
not received these services at the time of the 
MMP interview. 
In order to specifically assess risky behaviors 
and receipt of prevention services after HIV 
infection, the analysis below was restricted to 
participants whose diagnosis of HIV had 
occurred at least 12 months earlier. Among the 
90 API participants diagnosed with HIV at least 
12 months prior to interview, 60 (66.7%) 
reported being sexually active in the preceding 
12 months. Among 50 participants who reported 
vaginal or anal intercourse in the past 12 
months, 27 (54.0%) reported having had 
unprotected intercourse. Non-injection drug use 
in the previous 12 months was reported by 
34 (37.8%) of API participants; of these, the 
most common drugs reported were marijuana 
(70.6%), amyl nitrate or “poppers” (20.6%), 
and crystal methamphetamine (14.7%). 
Although injection drug use at any time in the 
past was reported by 16 (17.8%) participants, 
<5% reported injection drug use in the preceding 
12 months. Alcohol use was more common, 
with 57 (63.3%) API participants reporting any 
alcohol use in the previous 12 months and 
11 (12.2%) reporting excessive alcohol use (≥5 
drinks for men and ≥4 drinks for women in one 
day) in the preceding 30 days. Regarding 
prevention services, 45 (50.0%) API participants 
reported receiving free condoms, 22 (24.4%) 
reported participating in an individual-level 
intervention, and 6 (6.7%) reported participating 
in a group-level intervention in the past 12 
months. 
Persons at Risk for HIV—MSM 
Participants of NHBS 
For this report, we summarize the results from 
two descriptive analyses of 2008 NHBS data. 
The first characterizes API MSM who 
participated in NHBS and did not report a 
previous positive test result or diagnosis (i.e., 
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those considered to be at risk for HIV infection) 
and the second describes the prevalence of HIV 
infection among API MSM who completed 
NHBS HIV testing and had a negative or 
confirmed positive test result. 
CHARACTERISTICS OF AT-RISK API MSM 
Of 8,175 men participating in NHBS who 
reported having sex with another man in the 12 
months preceding the NHBS interview, 
completed the interview, and did not report a 
previous HIV-positive test result or diagnosis 
(15), 258 (3.2%) were API. Among these, most 
were 25–39 years of age (65.8%), were born 
outside of the United States (57.0%), and had 
some education beyond high school (88.8%) 
(see Appendix for Table A9). Among those who 
were foreign-born, the most commonly reported 
country of birth was the Philippines (36.1%). 
While 90.7% of API MSM reported being gay, 
8.5% self-identified as bisexual. Most (70.9%) 
reported having private health insurance, but a 
substantial percentage (23.6%) had no health 
insurance.  
In the 12 months preceding the NHBS interview, 
140 (54.3%) of API MSM participants reported 
having had unprotected anal or vaginal sex. Of 
the 134 MSM who reported having had 
unprotected anal sex with a male partner, 98 
(73.1%) reported unprotected anal sex with a 
main male partner,n and 55 (41.0%) reported 
unprotected anal sex with a casual male partner.o 
Of the 18 API MSM who reported sex with both 
male and female partners, <30% reported 
unprotected anal sex with their male partners, 
and 44.4% reported unprotected vaginal or anal 
sex with their female partners.  
When questioned about behaviors during their 
most recent sexual encounter with a male 
partner, 118 men reported sex with a main 
                                                            
partner, and 140 men reported sex with a casual 
partner. Unprotected anal intercourse was 
reported by 37.3% of those who had insertive 
anal intercourse with a main partner and by 
28.0% of those who had insertive anal 
intercourse with a casual partner. Unprotected 
receptive anal intercourse was reported by 
44.0% of those who had receptive anal 
intercourse with a main partner and by 35.4% of 
those who had receptive anal intercourse with a 
casual partner (see Appendix for Table A10).  
Alcohol use was prevalent, with 220 (85.3%) 
API MSM reporting current use, 25 (9.7%) 
reporting heavy use (consuming >2 alcoholic 
beverages per day on average during the 30 days 
before the interview), and 102 (39.5%) reporting 
excessive or “binge” drinking (i.e., consuming 
more than 5 alcoholic beverages at one sitting 
during the 30 days preceding the interview) (15). 
A total of 114 (44.2%) reported using non-
injection drugs in the past 12 months, and 85 
(32.9%) reported using alcohol or drugs during 
their most recent sexual encounter with a male 
partner (see Appendix for Table A10).  
Among 235 participants who reported ever 
having been tested for HIV, 76 (32.3%) had not 
been tested during the past 12 months. Of the 
158 participants who tested within the past 12 
months, the most common testing venues were a 
private physician’s office (28.5%), an HIV 
counseling and testing site (24.7%), and a public 
health clinic or community health center 
(19.0%). Among 99 API MSM participants who 
had not been tested for HIV in the preceding 12 
months, the most common reported reasons for 
not getting tested were the belief that they were 
at low risk for HIV (74.7%), fear of finding out 
that they were infected (32.3%), concern that 
someone would find out the test results (24.2%), 
and not having the time to get tested (18.2%). 
A total of 44 (17.1%) API MSM reported 
participating in any HIV prevention service or 
program in the preceding 12 months. By type of 
service or program, 32 (12.4%) participated in 
an individual-level intervention, and 16 (6.2%) 
participated in a group-level intervention. 
n  A main partner is defined as a sex partner with 
whom the participant feels committed to above 
anyone else (e.g., boyfriend, spouse, significant 
other, or life partner). 
o  A casual partner is defined as a sex partner with 
whom the participant does not feel committed to or 
does not know very well. 
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PREVALENCE OF HIV INFECTION 
This analysis examined data on men 
participating in NHBS who reported having sex 
with another man in the 12 months preceding the 
NHBS interview, completed both the interview 
and HIV testing for NHBS, and either had a 
negative or confirmed positive HIV test result 
(16). Data on participants who had indeterminate 
test results or who reported being HIV-positive 
but who had negative NHBS HIV test results 
were excluded to avoid the potential for 
misclassification of HIV infection status. 
Among the 8,153 MSM included in the analysis 
(16), 247 (3.0%) were API. Of the 247 API 
MSM, 25 (10.1%) had positive HIV test results. 
The HIV prevalence was highest among persons 
30–39 years of age (18.4%) compared to those 
18–24 (0%), 25–29 (6.7%), or ≥40 (<15%) years 
of age. The HIV prevalence was 11.3% among 
foreign-born and 8.6% among those born in the 
United States; 20.0% among those with high 
school education or less compared to 8.8% 
among those with more than high school 
education; 20.8% among those with an annual 
household income <$20,000 compared to 9.1% 
among those with income of $20,000–$39,999 
and 7.0% among those with income of $40,000 
or more; 15.0% among those with no insurance 
compared to 8.6% among those with private or 
public health insurance; and 17.5% among those 
who had never been tested for HIV or had not 
been tested in the past 12 months compared to 
4.9% among those who had been tested in the 
past 12 months (see Appendix for Table A11). 
Among those testing positive for HIV, 11 
(44.0%) did not report being HIV infected 
during the interview; of these, most (63.6%) had 
reported having never been tested previously or 
having been tested more than 12 months before 
the interview. 
DISCUSSION 
Persons with HIV Disease 
The percentage of Asians and NHPIs who were 
diagnosed with HIV were lower than the 
percentages for members of other racial and 
ethnic groups in the United States during 2010. 
Asians comprised 4.7% of the U.S. population in 
2010 and 1.7% of HIV diagnoses in 46 states 
and 5 U.S. dependent areas and NHPIs made up 
0.2% of the U.S. populationp and 0.1% of HIV 
diagnoses in 2010. 
Although the relative number of Asian and 
NHPIs infected with HIV may be small in the 
United States, Asians, in particular, represent a 
heterogeneous group. The racial group of 
“Asian” includes a number of different ethnic 
populations from different parts of the world, 
with different languages and social norms. In 
addition, the majority of HIV-infected Asians in 
the United States are foreign-born and thus 
factors such as acculturation, language, and 
socioeconomic status may further compound the 
challenge to find and deliver the appropriate 
prevention messages to individuals in this 
heterogeneous group.  
The median CD4+ T-lymphocyte count at the 
time of HIV diagnosis (182 cells/µL) for Asians 
suggests that most Asians were diagnosed late in 
the course of their infection and that there may 
have been missed opportunities to reduce HIV 
morbidity, mortality, and forward transmission. 
In addition, a telephone survey conducted 
among persons ≥18 years of age in the United 
States and 3 territories found that Asians, despite 
having similar HIV risks, were less likely to 
report having ever been tested for HIV when 
compared to all other races/ethnicity 
combined (13). Multiple cultural and social 
factors, including a lack of perceived individual 
risk, may contribute to the lower rate of HIV 
testing and to late HIV diagnoses among 
Asians (13,17). 
Little published information is available about 
NHPIs and HIV. Because of the methods 
adopted for surveillance in terms of 
race/ethnicity categorization, the actual number 
of NHPIs who are HIV-infected is higher than 
what has been estimated. Prior to 2003, a 
combined category of Asian and Native 
Hawaiian or Other Pacific Islander was used to 
report race. Current cumulative case counts for 
                                                            
p  U.S. dependent areas’ population not included. 
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Asians also include counts of NHPIs that cannot 
be separated from Asians prior to 2003. As a 
result, current cumulative estimates for NHPI 
are underestimates. Additionally, the majority of 
NHPIs self-identify as multiracial, as reported 
from U.S. Census Bureau data (see Chapter 1, 
page 17). Surveillance data, however, are most 
commonly derived from medical encounter 
information, which may include a subjective 
interpretation of race by healthcare providers 
and others.  
HIV data do not represent all U.S. reporting 
jurisdictions. Not until 2013 will all local and 
state health department HIV cases be aggregated 
and summarized into national data. Until then, 
Hawaii, a state with large Asian and NHPI 
populations, is not included in HIV estimates. In 
the analysis that examined geographic 
distribution of Asians and NHPIs affected by 
HIV, the list of the top 10 states with the largest 
number of Asians and NHPIs was based on data 
for persons living with AIDS. Examination of 
the relative distribution of demographic and risk 
characteristics for persons diagnosed with AIDS 
from all reporting jurisdictions and the subset 
diagnosed with HIV infection from name-based 
reporting jurisdictions are similar (see Table 5), 
however. Our analysis provides interim 
information until 2013 when all reporting 
jurisdictions’ data for HIV disease can be 
analyzed together. 
National HIV Surveillance System data are 
limited to what data are collected and reported. 
Because of the need to create a standardized data 
collection form that all local and state health 
departments will use, important information for 
a risk group may not be collected. For example, 
racial ethnicities (e.g., Thai, Chinese, Korean, 
etc.) are not routinely collected. Although 
information about country of birth is collected, it 
is not known when HIV infection occurred (i.e., 
in the United States or the country of birth). The 
degree of acculturation as assessed by year of 
immigration to the United States and whether 
English is spoken at home—information that 
may help better target education and prevention 
efforts—is not routinely collected. Some studies 
have undertaken collection of such information 
but they are often limited to a region or state and 
cannot provide a national snapshot. 
Persons in Care for HIV Disease 
API comprise a small percentage of HIV-
infected persons in care in MMP, and this 
percentage is similar to the percentage reported 
among all persons diagnosed with HIV in 2007 
or 2008 (5). However, we found 40.4% of the 
API population in MMP to be foreign-born, in 
contrast to over two-thirds of APIs diagnosed 
with HIV disease and reported from case 
surveillance. It is unclear whether this under-
representation of foreign-born among API who 
are in care reflects a difference in engagement in 
care between foreign-born versus U.S.-born API 
rather than a difference in MMP participation. 
Nevertheless, language and cultural barriers to 
obtaining medical care among foreign-born API 
should be considered when designing 
interventions to link HIV-infected persons to 
care.  
Over two-thirds of HIV-infected APIs who are 
in care entered medical care within 3 months of 
their HIV diagnosis. However, the degree of 
retention in care over time is unknown. More 
than half of these individuals had an HIV 
diagnosis for 10 or more years; many had 
advanced HIV disease (42.6% reporting their 
lowest CD4 count as <200 cells/µL) (see Figure 
24). Nevertheless, among these APIs who were 
in care, a high percentage reported receiving 
ART and having an undetectable HIV viral load, 
indicators of successful engagement in HIV 
care.  
Previous studies have shown that the prevalence 
of risky sexual behaviors decrease after 
individuals become aware that they are HIV-
infected (18). Although the prevalence of 
unprotected vaginal or anal intercourse was high 
among the API MMP participants in this report, 
further investigation is needed to better 
understand these behaviors and the associated 
transmission risk. Nevertheless, given the 
importance of maintaining behaviors associated 
with low risk for HIV transmission over time, 
the reported participation in individual- or 
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group-level interventions appears low among the 
API MMP participants and suggests that greater 
efforts are needed to improve the availability 
and acceptability of these prevention services for 
these HIV-infected APIs.  
Alcohol and drug treatment interventions have 
been used to enhance HIV prevention activities 
because alcohol and drug use are associated with 
engagement in risky sexual behaviors. Among 
the API participants of MMP, the prevalence of 
noninjection drug use in the preceding 12 
months (37.8%) and excessive alcohol use in the 
preceding month (12.2%) were substantial. HIV 
care providers can play an important role in HIV 
prevention as well as in improving treatment 
adherence in their patients by screening for 
substance use problems, delivering prevention 
messages, and providing referrals for substance 
abuse treatment when appropriate.  
The MMP findings are subject to several 
limitations. First, although MMP was designed 
to produce nationally representative data on all 
HIV-infected persons in care, it was not 
specifically designed to produce representative 
data for HIV-infected APIs. Thus, our reported 
results may not be generalizable to all HIV-
infected APIs in care in the United States. 
Second, because the survey was conducted as an 
in-person interview, responses to some questions 
(e.g., drug use, sexual behaviors) are subject to 
social desirability bias. Finally, self-reported 
information, in general, and on CD4+ T-
lymphocyte counts and HIV viral load results, 
specifically, are subject to the participant’s 
ability to recall the clinical information.  
Persons at Risk for HIV: MSM 
Participants of NHBS 
In the United States., MSM continue to bear the 
largest burden of HIV infection, and among 
APIs, this is also true (5,13). Therefore, efforts 
to reduce the risk for HIV infection among 
MSM remain a critical part of HIV prevention. 
Based on the NHBS data in this report, efforts to 
reduce HIV risk among API MSM should 
consider cultural and language issues facing API 
men, particularly because a large percentage of 
this population is foreign-born. In addition, 
prevention efforts may need to focus on API 
MSM with low socioeconomic status, as HIV 
prevalence is higher among API MSM of lower 
socioeconomic status.  
As was observed with MSM of other 
race/ethnicity in NHBS (15), risky sexual 
practices and noninjection drug use were also 
commonly seen among API MSM. However, 
some of the highest risk behaviors, such as 
unprotected receptive anal intercourse with a 
casual partner or with a partner whose HIV 
status is positive or unknown, were less 
frequently reported among API participants than 
among all NHBS participants as a whole (15). 
The reason for this is not clear, but cultural and 
socioeconomic factors may explain some of 
these differences, particularly given the higher 
levels of education, household income, and 
insurance coverage seen among API 
participants, relative to NHBS participants in 
general (13). Higher educational attainment, 
higher income, and having health insurance 
indicate greater access to health resources, 
which may affect knowledge and behaviors.  
Because of the high risk for HIV infection 
among MSM, CDC currently recommends that 
sexually active MSM get tested for HIV at least 
once per year (19). Although many API MSM in 
NHBS reported having been tested for HIV in 
the preceding 12 months, over one-third never 
tested or were tested more than 12 months 
before the interview. One of the most common 
reasons API MSM gave for not getting tested 
was a belief that they were at low risk for HIV 
infection, indicating the need for HIV education 
in this population. In addition, participation in 
individual- or group-level behavioral 
interventions, which have demonstrated 
effectiveness for reducing HIV risk behaviors, is 
reported by a small percentage of API MSM in 
NHBS. Because low participation rates have 
also been observed among MSM of other racial 
and ethnic groups (13), renewed effort to 
improve participation in these programs is 
needed.  
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The NHBS results should be interpreted with 
caution, given a number of limitations. Although 
NHBS includes a large number of MSM 
participants, the participants were sampled and 
recruited at selected venues, and would, 
therefore, not include MSM who do not attend 
such venues. As a result, the NHBS data may 
not be representative of MSM in the 
participating urban areas or those in states or 
cities outside of these areas. Similarly, the 
NHBS data on API MSM may not be 
representative of API MSM at the local or 
national level. In addition, because of the 
relatively small number of API MSM, the results 
within categories or subgroups should be 
interpreted with caution. Lastly, no statistical 
test was done to assess differences between 
groups, but our descriptive analyses provide 
some baseline information that can be refined 
and added to over time. 
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Figure 22.  Estimated rate* of HIV diagnoses among Asians, 2007–2010 
 
*  Per 100,000 population; Centers for Disease Control and Prevention. HIV Surveillance Report 2010, vol. 22. Page 
17, Table 1A (46 states) data used. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Published 
March 2012. Accessed April 6, 2012. 
Figure 23. Estimated rate* of HIV diagnoses among Native Hawaiians and Other Pacific Islanders, 
2007–2010 
 
*  Per 100,000 population; Centers for Disease Control and Prevention. HIV Surveillance Report 2010, vol. 22. Page 
17, Table 1A (46 states) data used. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Published 
March 2012. Accessed April 6, 2012. 
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Figure 24.  Self-reported lowest and most recent CD4+ T-lymphocyte counts among Asian and 
Native Hawaiian and Other Pacific Islander participants during the 12 months before 
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Table 5. Age distribution of Asians and Native Hawaiians and Other Pacific Islanders living with 
HIV disease through December 31, 2009  
 Asians  Native Hawaiians and Other Pacific Islanders 
 HIV*  AIDS†  HIV*  AIDS† 
Age group, years 
Estimated 
number %  
Estimated 
number %  
Estimated 
number %  
Estimated 
number % 
<15 53 0.6  7 0.1  1 0.2  3 0.6 
15–19 36 0.4  11 0.2  1 0.2  2 0.4 
20–24 241 2.9  51 1.0  29 4.7  4 0.8 
25–29 581 6.9  192 3.8  67 10.8  32 6.7 
30–34 1,024 12.2  435 8.5  87 14.0  41 8.5 
35–39 1,566 18.6  850 16.6  105 16.9  60 12.5 
40–44 1,605 19.1  1,008 19.7  103 16.6  97 20.2 
45–49 1,274 15.1  912 17.8  98 15.8  101 21.0 
50–54 919 10.9  683 13.4  66 10.6  70 14.6 
55–59 557 6.6  478 9.4  32 5.2  35 7.3 
60–64 330 3.9  284 5.6  17 2.7  19 4.0 
65+ 237 2.8  200 3.9  14 2.3  17 3.5 
Total 8,422   5,112  620   481  
Modified from Tables 17b and 18b, Centers for Disease Control and Prevention. HIV Surveillance Report 2010, vol. 22. Pages 
59, 62, 63. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Published March 2012. Accessed April 6, 2012. 
Column totals may differ from sum of estimated age groups counts because of rounding. 
* Data from 46 states and 5 U.S. dependent areas were used for these estimates. 
† Data from 50 states, the District of Columbia, and 6 U.S. dependent areas were used for these estimates. 
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Table 6. Transmission category among Asians and Native Hawaiians and Other Pacific Islanders 
living with HIV disease through December 31, 2009 
 
Asians  
Native Hawaiians and 
Other Pacific Islanders 
 HIV*  AIDS†  HIV*  AIDS† 
Category 
Estimated 
number %  
Estimated 
number %  
Estimated 
number %  
Estimated 
number % 
Males            
Men who have sex 
with men (MSM) 
5,609 81.8  3,283 77.7  425 84.0  317 80.7 
Injection drug use 
(IDU) 
286 4.2  228 5.4  18 3.6  21 5.3 
MSM & IDU 290 4.2  211 5.0  33 6.5  27 6.9 
Heterosexual contact 618 9.0  446 10.6  28 5.5  26 6.6 
Other 51 0.7  59 1.4  1 0.2  3 0.8 
Subtotal 6,854   4,226   506   393  
Females            
IDU 127 8.6  90 10.4  17 15.2  14 16.9 
Heterosexual contact 1,287 87.4  711 82.0  92 82.1  66 79.5 
Other 60 4.1  65 7.5  2 1.8  3 3.6 
Subtotal 1,473   867   112   83  
Children (<13 years)            
Perinatal 63 67.0  14 77.8  2 100.0  5 100.0 
Other 31 33.0  4 22.2  0 0.0  0 0.0 
Subtotal 94   18   2     
Modified from Tables 17b and 18b, Centers for Disease Control and Prevention. HIV Surveillance Report 2010, vol. 22. Pages 
59, 62, 63. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Published March 2012. Accessed April 6, 2012. 
Column subtotals may differ from sum of sex- and risk exposure-specific estimated counts due to rounding. 
* Data from 46 states and 5 U.S. dependent areas were used for these estimates. 
† Data from 50 states, the District of Columbia, and 6 U.S. dependent areas were used for these estimates. 
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Table A1. Distribution of population groups in the overall U.S. population, 2010 
Population Group  Number Percent 
Hispanic 50,477,594 16.3 
Non-Hispanic   
  American Indian and Alaska Native 2,247,098 0.7 
  Asian 14,465,124 4.7 
  Black or African American 37,685,848 12.2 
  Native Hawaiian and Other Pacific Islander 481,576 0.2 
  White 196,817,552 63.7 
  Other race 604,265 0.2 
  Two or more races 5,966,481 1.9 
Total 308,745,538 100.0 
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Table A2. Top 20 U.S. metropolitan or micropolitan statistical areas with the largest Asian 
populations, 2010 






1 New York-Northern New Jersey-Long Island, NY-NJ-PA 18,897,109 1,860,840 
2 Los Angeles-Long Beach-Santa Ana, CA  12,828,837 1,858,148 
3 San Francisco-Oakland-Fremont, CA  4,335,391 994,616 
4 San Jose-Sunnyvale-Santa Clara, CA  1,836,911 566,764 
5 Chicago-Joliet-Naperville, IL-IN-WI  9,461,105 526,857 
6 Washington-Arlington-Alexandria, DC-VA-MD-WV  5,582,170 513,919 
7 Honolulu, HI  953,207 410,019 
8 Seattle-Tacoma-Bellevue, WA  3,439,809 389,309 
9 Houston-Sugar Land-Baytown, TX  5,946,800 384,596 
10 Dallas-Fort Worth-Arlington, TX  6,371,773 337,815 
11 San Diego-Carlsbad-San Marcos, CA  3,095,313 328,058 
12 Philadelphia-Camden-Wilmington, PA-NJ-DE-MD  5,965,343 293,656 
13 Boston-Cambridge-Quincy, MA-NH  4,552,402 292,786 
14 Atlanta-Sandy Springs-Marietta, GA  5,268,860 252,510 
15 Sacramento--Arden-Arcade--Roseville, CA  2,149,127 250,690 
16 Riverside-San Bernardino-Ontario, CA  4,224,851 249,899 
17 Minneapolis-St. Paul-Bloomington, MN-WI  3,279,833 187,047 
18 Las Vegas-Paradise, NV  1,951,269 165,121 
19 Detroit-Warren-Livonia, MI  4,296,250 140,558 
20 Phoenix-Mesa-Glendale, AZ  4,192,887 134,415 
Source: 2010 Census National Summary File of Redistricting Data (Table P2, Race and Hispanic Origin). 
For an explanation of metropolitan and micropolitan statistical areas, see http://www.census.gov/population/metro/. 
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Table A3. Top 20 U.S. metropolitan or micropolitan statistical areas with the largest Native 
Hawaiian and Other Pacific Islander populations, 2010 




Hawaiian and Other 
Pacific Islander 
population 
1 Honolulu, HI Metro Area 953,207 86,235 
2 Los Angeles-Long Beach-Santa Ana, CA Metro Area 12,828,837 30,821 
3 San Francisco-Oakland-Fremont, CA Metro Area 4,335,391 29,761 
4 Seattle-Tacoma-Bellevue, WA Metro Area 3,439,809 27,275 
5 Hilo, HI Micro Area 185,079 20,970 
6 Salt Lake City, UT Metro Area 1,124,197 15,686 
7 Kahului-Wailuku, HI Micro Area 154,834 15,257 
8 Sacramento–Arden-Arcade–Roseville, CA Metro Area 2,149,127 14,874 
9 San Diego-Carlsbad-San Marcos, CA Metro Area 3,095,313 13,504 
10 Las Vegas-Paradise, NV Metro Area 1,951,269 12,474 
11 Riverside-San Bernardino-Ontario, CA Metro Area 4,224,851 11,694 
12 Portland-Vancouver-Hillsboro, OR-WA Metro Area 2,226,009 9,812 
13 Phoenix-Mesa-Glendale, AZ Metro Area 4,192,887 8,212 
14 San Jose-Sunnyvale-Santa Clara, CA Metro Area 1,836,911 6,317 
15 Anchorage, AK Metro Area 380,821 5,990 
16 Kapaa, HI Micro Area 67,091 5,716 
17 Dallas-Fort Worth-Arlington, TX Metro Area 6,371,773 5,431 
18 Fayetteville-Springdale-Rogers, AR-MO Metro Area 463,204 5,000 
19 New York-Northern New Jersey-Long Island, NY-NJ-
PA Metro Area 
18,897,109 4,859 
20 Provo-Orem, UT Metro Area 526,810 3,832 
Source: 2010 Census National Summary File of Redistricting Data (Table P2, Race and Hispanic Origin). 
For an explanation of metropolitan and micropolitan statistical areas, see http://www.census.gov/population/metro/. 
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Table A4. Selected characteristics for hepatitis B testing and testing positive among Asians in 4 
health plans* 
  
Asian members in 
4 health plans†  
 Had at least one positive test (surface 
antigen or DNA§) among those tested¶ 
% Total N  % Row (n/N) 
Overall 100.0% 60,097  4.2% (671/16,044) 
Sex        
    Female 59.1% 35,517  4.0% (429/10,721) 
   Male 40.9% 24,580  4.6% (242/5,323) 
Age group, years        
    <30 15.5% 9,282  3.3% (84/2,548) 
   30–39  17.2% 10,316  3.8% (152/4,022) 
   40–49  17.9% 10,764  5.0% (151/3,024) 
   50–59  18.8% 11,299  5.8% (153/2,661) 
   60–69  14.0% 8,438  4.1% (78/1,902) 
   70–79  9.1% 5,442  3.2% (36/1,110) 
   ≥80 7.6% 4,556  2.2% (17/777) 
Median household income**    
    <$30K 6.1% 3,647  3.8% (35/931) 
   $30–49K 34.4% 20,641  4.5% (254/5,669) 
   $50–74K 43.7% 26,279  3.9% (270/6,855) 
   ≥$75K 13.0% 7,834  4.5% (103/2,272) 
   Not reported 2.8% 1,696  2.8% (9/317) 
*  The four health plans are Geisinger Health System, Danville, PA; Henry Ford Health System, Detroit MI; Kaiser 
Permanente-Northwest, Portland, OR; and Kaiser Permanente-Hawaii. 
†  Excluded in study if had a prior documented infection with hepatitis B at health plan entry. 
§  Laboratory markers indicating the presence of circulating hepatitis B virus.  
¶  The denominator used to derive the percent of prevalent positives was the number of Asian patients who were 
ever tested for hepatitis B. 
**  Census tract geocoding, defined as matching patient address information to census tract data, was used to obtain 
median household income information. 
Source: Spradling PR, Rupp L, Moorman AC, et al. Hepatitis B and C virus infection among 1.2 million persons 
with access to care: Factors associated with testing and infection prevalence. Clin Infect Dis [in press]. 
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Table A5. Selected characteristics for hepatitis B testing and testing positive among Native 
Hawaiians and Other Pacific Islanders in 4 health plans* 
  
NHPI† members in 
4 health plans§ 
 Had at least one positive test (surface 
antigen or DNA¶) among those tested** 
% Total N  % Row (n/N) 
Overall 100.0% 28,492  2.5% (180/7,294) 
Sex       
   Female 55.0% 15,667  2.2% (99/4,596) 
   Male 45.0% 12,825  3.0% (81/2,698) 
Age group, years       
   <30 25.9% 7,390  2.3% (47/2,027) 
   30–39  19.8% 5,641  1.9% (34/1,812) 
   40–49  18.4% 5,232  3.5% (45/1,288) 
   50–59  15.9% 4,527  2.6% (26/992) 
   60–69  11.1% 3,173  3.1% (21/682) 
   70–79  5.9% 1,675  0.6% (2/346) 
   >80 3.0% 854  3.4% (5/147) 
Median household income††       
   <$30K 5.3% 1,514  1.2% (5/411) 
   $30–49K 34.9% 9,942  2.2% (55/2,509) 
   $50–74K 47.4% 13,516  2.8% (97/3,488) 
   >$75K 11.0% 3,122  2.7% (22/816) 
   Not reported 1.4% 398  1.4% (1/70) 
*  The four health plans are Geisinger Health System, Danville, PA; Henry Ford Health System, Detroit MI; Kaiser 
Permanente-Northwest, Portland, OR; and Kaiser Permanente-Hawaii. 
†  Native Hawaiian and Other Pacific Islander. 
§  Excluded in study if had a prior documented infection with hepatitis B at health plan entry. 
¶  Laboratory markers indicating the presence of circulating hepatitis B virus. 
**  The denominator used to derive the percent of prevalent positives was the number of Native Hawaiians and 
Other Pacific Islanders patients who were ever tested for hepatitis B. 
†† Census tract geocoding, defined as matching patient address information to census tract data, was used to obtain 
median household income information. 
Source: Spradling PR, Rupp L, Moorman AC, et al. Hepatitis B and C virus infection among 1.2 million persons 
with access to care: Factors associated with testing and infection prevalence. Clin Infect Dis [in press]. 
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Table A6. Selected characteristics for hepatitis C testing and testing positive among Asians in 4 
health plans* 
 
Asian members in 
4 health plans†  
Ever tested positive (antibody§) among 
those tested¶ 
 
% Total N  % Row (n/N) 
Overall 100.0% 60,177  4.3% (391/9,025) 
Sex      
    Female 59.1% 35,559  4.0% (213/5,289) 
   Male 40.9% 24,618  4.8% (178/3,736) 
Age group, years      
    <30 15.5% 9,302  3.9% (42/1,067) 
   30–39  17.2% 10,342  2.3% (35/1,535) 
   40–49  17.9% 10,783  3.3% (57/1,723) 
   50–59  18.8% 11,311  7.2% (136/1,888) 
   60–69  14.0% 8,443  4.9% (68/1,390) 
   70–79  9.0% 5,437  4.1% (34/834) 
   ≥80 7.6% 4,559  3.2% (19/588) 
Median household income**      
    <$30K 6.1% 3,649  2.8% (15/545) 
   $30–49K 34.3% 20,666  4.7% (144/3,048) 
   $50–74K 43.7% 26,312  4.5% (176/3,891) 
   ≥$75K 13.1% 7,854  4.0% (54/1,348) 
   Not reported 2.8% 1,696  1.0% (2/193) 
*  The four health plans are Geisinger Health System, Danville, PA; Henry Ford Health System, Detroit MI; Kaiser 
Permanente-Northwest, Portland, OR; and Kaiser Permanente-Hawaii. 
†  Excluded in study if had a prior documented infection with hepatitis C at health plan entry. 
§  Laboratory marker indicating past or present infection with hepatitis C. 
¶ The denominator used to derive the percent of prevalent positives was the number of Asian patients who were 
ever tested for hepatitis C. 
** Census tract geocoding, defined as matching patient address information to census tract data, was used to obtain 
median household income information. 
Source: Spradling PR, Rupp L, Moorman AC, et al. Hepatitis B and C virus infection among 1.2 million persons 
with access to care: Factors associated with testing and infection prevalence. Clin Infect Dis [in press]. 
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Table A7. Selected characteristics for hepatitis C testing and testing positive among Native 
Hawaiians and Other Pacific Islanders (NHPI) in 4 health plans* 
 
NHPI members in 4 health plans†  
Ever tested positive (antibody§) 
among those tested¶ 
% Total N  % Row (n/N) 
Overall 100.0% 28,494  4.4% (175/3,999) 
Sex      
    Female 55.0% 15,667  3.5% (78/2,211) 
   Male 45.0% 12,827  5.4% (97/1,788) 
Age group, years    
     <30 25.9% 7,391  3.0% (26/869) 
   30–39  19.8% 5,641  2.3% (19/824) 
   40–49  18.3% 5,227  5.1% (37/730) 
   50–59  15.9% 4,529  7.0% (48/682) 
   60–69  11.1% 3,176  6.5% (33/509) 
   70–79  5.9% 1,676  3.7% (10/269) 
   ≥80 3.0% 854  1.7% (2/116) 
Median household 
income**   
 
     <$30K 5.3% 1,514  5.7% (13/230) 
   $30–49K 34.9% 9,950  3.7% (50/1,361) 
   $50–74K 47.4% 13,516  4.4% (86/1,940) 
   ≥$75K 10.9% 3,117  5.7% (25/438) 
   Not reported 1.4% 397  3.3% (1/30) 
*  The four health plans are Geisinger Health System, Danville, PA; Henry Ford Health System, Detroit MI; Kaiser 
Permanente-Northwest, Portland, OR; and Kaiser Permanente-Hawaii. 
†  Excluded in study if had a prior documented infection with hepatitis C at health plan entry. 
§  Laboratory marker indicating past or present infection with hepatitis C. 
¶  The denominator used to derive the percent of prevalent positives was the number of Native Hawaiians and 
Other Pacific Islanders patients who were ever tested for hepatitis C. 
** Census tract geocoding, defined as matching patient address information to census tract data, was used to obtain 
median household income information. 
Source: Spradling PR, Rupp L, Moorman AC, et al. Hepatitis B and C virus infection among 1.2 million persons 
with access to care: Factors associated with testing and infection prevalence. Clin Infect Dis [in press]. 
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Table A8.  Characteristics of Asian or Native Hawaiian and Other Pacific Islander (API) 
Participants of the Medical Monitoring Project, 2007–2009 
Characteristics N* (%) 
Age group, years   
18–34 19  (20.2) 
35–44 29  (30.9) 
45–54  36  (38.3) 
≥55 10  (10.6) 
Gender    
Male 77  (81.9) 
Female  14  (14.9) 
Country of birth   
United States 56  (59.6) 
Outside United States 38  (40.4) 
Education   
<High school 13  (13.8) 
High school diploma or GED credential 15  (16.0) 
>High school 66  (70.2) 
Health insurance or coverage, past 12 months    
Yes 80  (85.1) 
No 14  (14.9) 
Received public assistance, past 12 months    
Yes 45  (47.9) 
No 49  (52.1) 
Year(s) since HIV diagnosis    
<5  20  (21.3) 
5–9  22  (23.4) 
≥10 years 48  (51.1) 
Total 94  (100) 
*  Numbers might not add to total because of missing or unknown data. 
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Table A9. Characteristics of Asian or Native Hawaiian and Other Pacific Islander (API) men who 
have sex with men participants* of the National HIV Behavioral Surveillance System 
(NHBS), 2008 
Characteristics N†     (%) 
Age group (interview data), years  
18–24  46 (17.8) 
25–29  77 (29.8) 
30–39  93 (36.0) 
≥40   42 (16.3) 
Sexual identity  
Gay  234 (90.7) 
Bisexual  22 (8.5) 
Race  
Asian  199 (77.1) 
Native Hawaiian and Other Pacific Islander  59 (22.9) 
Country of birth   
United States  111 (43.0) 
Outside United States  147 (57.0) 
Education  
Not more than high school diploma or equivalent  29 (11.2) 
More than high school  229 (88.8) 
Annual household income  
<$20,000  47 (18.2) 
$20,000–$39,999  55 (21.3) 
$40,000–$74,999  79 (30.6) 
≥$75,000  76 (29.5) 
Health insurance or coverage, past 12 months   
None   61 (23.6) 
Private only  183 (70.9) 
Public only  13 (5.0) 
Total  258 (100) 
*  This analysis included API men who reported having sex with another man in the 12 months preceding the 
NHBS interview, completed the interview, and did not report being HIV positive.  
†  Numbers might not add to total because of missing or unknown data. 
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Table A10.  Among Asian or Native Hawaiian and Other Pacific Islander (API) men who have sex 
with men*, number† and percentage reporting anal sex during their most recent sexual 
encounter with a male partner, by type and HIV status of partner and substance use 
during encounter, National HIV Behavioral Surveillance System (NHBS), 2008 
Characteristic 











Partner type        
Main 83 (70.3) 31 (37.3)  84 (71.2) 37 (44.0)  118 
Casual 82 (58.6) 23 (28.0)  79 (56.4) 28 (35.4)  140 
Partner’s HIV status        
Not infected 93 (50.5) 29 (31.2)  89 (48.4) 33 (37.1)  184 
Infected or unknown 31 (41.9) 9 (29.0)  26 (35.1) 9 (34.6)  74 
Alcohol or drug use 








Yes 43 (50.6) 14 (32.6)  43 (50.6) 13 (30.2)  85 
No 81 (46.8) 24 (29.6)  72 (41.6) 29 (40.3)  173 
Total 124 (48.1) 38 (30.6)  115 (44.6) 42 (36.5)  258 
*  This analysis included API men who reported having sex with another man in the 12 months preceding the 
NHBS interview, completed the interview, and did not report being HIV positive. 
†  Numbers might not add to total because of missing or unknown data. 
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Table A11. Prevalence of HIV infection, by selected characteristics of Asian or Native Hawaiian 
and Other Pacific Islander (API) men who have sex with men who were tested for 
HIV* as part of the National HIV Behavioral Surveillance System (NHBS), 2008 
 
Number tested for HIV† 
Tested positive for HIV 
n (%) 
Age group, years 
  18–24 45 0 (0.0) 
25–29 75 5 (6.7) 
30–39 87 16 (18.4) 
40+ 40 <5 (<15) 
Country of birth  
 United States 105 9 (8.6) 
Outside United States 142 16 (11.3) 
Education  
 Not more than high school 
diploma or equivalent 
30 6 (20.0) 
More than high school 217 19 (8.8) 
Annual household income  
 0 to $19,999 48 10 (20.8) 
$20,000 to $39,999 55 5 (9.1) 
$40,000 or more 143 10 (7.0) 
Health insurance  
 Private only 170 12 (7.1) 
None or public only 76 13 (17.1) 
Previous HIV test  
 Past 12 months 143 7 (4.9) 
Never tested or tested more 
than 1 year ago 
103 18 (17.5) 
Total 247 25 (10.1) 
*  This analysis included API men who reported having sex with another man in the 12 months preceding the 
NHBS interview, completed both the interview and HIV testing for NHBS, and either had a negative or 
confirmed positive HIV test result. 
†  Numbers might not add to total because of missing or unknown data. 
 
